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Abstract 
Life is anti-entropic and highly organized phenomenon with two characteristics 
reinforcing each other: homochirality and the stereospecific catalysis of chemical reactions. The 
exclusive presence of L-amino acids and R-sugars in living world well depict this. 
Hypothetically, the amino acids and sugars of reverse chirality could form a parallel kingdom 
which is highly orthogonal to the present world. The components from this mirror kingdom, such 
as protein or nucleic acid, will be much more resistant to the defensive mechanism of present 
living system, which could be of great value. Therefore, by gradually rewiring the present bio-
machineries, we look to build a bridge leading us to the space of mirror-imaged biomolecules. 
We begin by investigating protein synthesis with mirror amino acid since most amino acids 
contain one chiral center to be inversed comparing to sugars. In this work, we analyzed three 
stages critical for the incorporation of D-amino acid into ribosomal protein synthesis: amino 
acylation, EF-Tu binding of amino acyl-tRNA and delivery bias, and ribosome catalyzed 
peptidyl transfer.  We have demonstrated that the affinity between EF-Tu and amino acyl-tRNA 
plays critical role on D-amino acid incorporation, and built a platform aimed to select for 
ribosome tolerating D-amino acid better.  
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Non-ribosomal peptide and polyketide synthesis are another important class of modular 
biomolecules synthesis. Polyketides, which compose one of the largest groups of therapeutic 
natural products known today, are built by series of modular polyketide synthetases in bacteria, 
fungi and plants. Intrigued by their interaction with critical pathways in the cell and hence their 
therapeutic value, researchers have synthesized numerous polyketides either one by one or in a 
combinatorial manner. However, both these approaches become inefficient when a large set of 
scaffold-variant libraries of polyketide is required for drug development.  In an effort to address 
this issue, we propose to utilize a bacterial translation system to build polyketide or polyketide-
peptide hybrid scaffolds. More specifically, tRNA with a thiol in place of the hydroxyl group at 
the 3’-terminus is synthesized, loaded with malonyl ketide substrate and subjected into an in 
vitro translation system.     
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Chapter 1: Introduction  
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The self-sustention of biological chirality among amino acid and sugar 
enantiomers 
Chirality was first described in 1848 by Louis Pasteur for spontaneously resolved crystals 
of sodium ammonium tartrate salt having shapes non-superposable to their mirror image (Flack, 
2009; Pasteur, 1848). These two chiral tartrate salt crystals preserve their optical activity in 
solution, in contrast to quartz which loses optical activity when melted. While knowing nothing 
about molecular structure at that time, Pasteur demonstrated that optical activity can result from 
intrinsic asymmetry of compounds. Later in 1874, J. H. Van’t Hoff and J. A. Le Bel attributed 
chirality to spatial isomers based on carbon tetrahydron structure hypothesis proposed earlier by 
Kekulé in 1862 (Hoff and Werner, 1898). This idea widely accepted as it successfully explained 
many compound’s optical activity with known constitutional structure.  In the 1800s, several 
amino acids were isolated from organic source (ex. asparagine from asparagus juice in 1806, 
cysteine from urinary calculus in 1810, leucine from milk curd in 1819) or differential hydrolysis 
of protein (ex. glycine from gelatin in 1820), and many of their optical activity were 
demonstrated (Vickery and Schmidt, 1931). In early 1910s, Emil Fischer resolved several optical 
isomers of synthetic racemic amino acids (ex. tyrosine, valine, serine and phenylalanine by 
brucine salt). He along with Franz Hofmeister proved that proteins are polymer of amino acids 
with amide linkages, by showing close resemblance of synthetic polypeptides to proteins in 
many properties such as water solubility, reactivity to biuret test, and susceptibility to proteases 
such as trypsin. Fischer and his colleague also found that racemic peptides (ex. carbethoxyl-
glycyl-dl-leucine) are hydrolyzed asymmetrically by pancreas extract, and if pure trypsin is used, 
only peptides with native configuration are digested (Plimmer, 1913). This is probably the 
earliest evidence that natural machineries such as proteins, not only are composed predominately 
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by elements with specific configuration, but also interact preferentially with targets containing 
elements of the same configuration. In addition, nucleosides and the containing sugar are another 
class of optically active compounds. Not long after the establish of DNA double helix and 
Watson-Crick base pairing model in 1953, the L-form ribonucleotides were synthesized, 
followed by L-2’-deoxyoligonucleotides and L-oligonucleotides (Anderson et al., 1984; Holý 
and Šorm, 1971). Coinciding with Fischer’s “Key and Lock” stereospecific hypothesis (Fischer, 
1894) for proteins, the L-form DNA doesn’t hybridize with complementary oligos of its mirror-
form, i.e. D-form.  
From Miller’s spark discharge experiment (Miller, 1953; Parker et al., 2011), one can 
speculate that early inorganic production of amino acid were racemic, and presumably other 
small organic molecules as well. Although it remains elusive how the primitive earth biased 
toward the current chirality, evidence is found on the spontaneous resolving and concatenating of 
enantiomeric primordial organic compounds.  One example is the polymerization of D- or L-γ-
benzylglutamic acid anhydrides. Blout and Idelson found that polymerization elongated from D-
(or L)-homopolymers seeds show no preference for D- over L-monomers in a racemic pool. 
However, when L-homopolymer seed is placed in enriched pools of L-amino acid anhydride, the 
chain grows faster and longer than when mixed-DL-polymer seed is used. This is due to the 
stabilization of α-helix conformation in the seed and presumably the intermediate (Idelson and 
Blout, 1958). Another example is the template directed oligomerization of activated nucleoside. 
G. F. Joyce found that the presence of poly-D-cytidine-5’-monophosphate template greatly help 
polymerization of D-guanosine-5’-phosphoimidazole but not the L-form antipode (Joyce et al., 
1984) when reactions were carried out separately. However, if the reaction is carried out in 
racemic mixture, the L-form antipode acts as chain terminator, which blocks the sequential 
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addition or D-guanosine monophosphate. These effects of enantiomeric cross-inhibitions show  
that some repetitive structural characteristics formed by homopolymers are critical to their 
catalytic abilities. This effect explains the necessity of homochirality in primitive forms of life, 
i.e. macromolecules catalyze their own propagation. In fact, biomolecule homochirality and 
stereospecific catalysis of its propagation are interdependent and equally important features of 
living system replication.   
How do cells interact with D-amino acids and L-sugars? 
Given the potential origin of biological homochirality and its importance to 
biomacromolecule’s self-replication, even it is not clear when and how one chirality kingdom 
overwhelmed the other, i.e. L-amino acid and D-ribose versus D-amino acid and L-ribose, it is 
not surprising to see that homochiral biopolymers from one kingdom of chirality evolved 
defensive mechanisms to prevent the incorporation of units from its enantiomeric antipodes. 
However, this doesn’t exclude the potential that besides the core, self-replicating activity, these 
homochiral biopolymers can develop beneficiary interaction with certain element of its 
enantiomeric antipodes. Indeed, some D-amino acids and L-sugar still exist in current organisms 
of L-amino acid and D-sugar world, and they perform specific functions stereospecifically as 
well. Example are the use of D-alanine in bacterial cell wall (Neuhaus and Baddiley, 2003), D-
serine as a neurotransmitter in brain (Wolosker, 2011) and L-arabinose for glycoprotein in plants 
(Burget, 2003), and many of them could both be synthesized de novo (Heck et al., 1996; 
Yoshimura and Esak, 2003) and enter catabolism pathway as nitrogen or carbon source (Shimizu 
et al., 2012; Yurimoto et al., 2000). In monomeric compounds, the role of these enantiomeric 
antipodes toward present cellular machinery resembles metabolites more than constitutive ones 
in general.    
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On the other hand, one would suggest that these enantiomeric antipodes, when appear as 
polymers or are placed into their antipodal polymers, would be inert toward a large proportion of 
the present biological machineries, since their interaction based on secondary and tertiary 
structures would be altered and very likely disrupted. Therefore designed polymers of these 
enantiomeric antipodes could achieve specific tasks in cells while remained orthogonal – more 
resistant to degradation, less antigenic and less perturbations to normal cellular functions. 
Several examples have demonstrated this idea. RNA spiegelmers, which is made out of all L-
ribonucleotide, are selected to bind specifically and tightly to protein targets and suppress their 
function (Vater and Klussmann, 2003). Few spiegelmers targeting diabetes and oncology have 
entered phase II clinical trials now (ref. NOXXON Pharma website). Several D-amino acid 
containing peptides of therapeutic potential have also been identified (Sun et al., 2012). In all 
cases above, they are found to possess much greater nuclease or protease resistant and hence 
have much longer half-life in vivo. It is interesting to note that epimerization of individual amino 
acids within proteins do not always disrupts their existing interaction with other proteins 
(Nakagawa et al., 2007; Tugyi et al., 2005), which implies that embedding add-in enantiomeric 
antipodal module to cellular machineries could selectively change their interaction network.   
However, the study of these polymers is greatly limited by their availability. SELEX 
(Tuerk and Gold, 1990) has been adapted in a genius way to make RNA spiegelmers, but still 
required to first synthesize the mirror image target chemically, which is very difficult when the 
target is a large protein. A similar situation is encountered when applying mirror-image phage 
display technique (Schumacher et al., 1996) to select for D-peptides. We are interested in these 
properties and potential applications of mirror image biopolymers and therefore seeking to 
develop a more efficient and broadly applicable way to build them.  
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Oligonucleotides and oligopeptides, no matter D or L-form, could be chemically 
synthesized in great lengths and in massive parallel fashion, by either ink-jet printing, 
electrochemical deprotection techniques or the more recent laser-based electrostatic printing of 
activated amino acid microparticles (Beyer et al., 2007; Breitling et al., 2009; Gao et al., 2004; 
Maurer et al., 2006).  Despite these advances on synthetic methods could generate oligos 
containing mirror image residues efficiently, one almost inevitably needs delicate methods to 
transform these oligos into a functional assembly with higher order structure. These methods are 
usually carried out by enzymes such as polymerase, ligase, etc., and are mostly stereospecific 
toward substrates.  Although several artificial ribozymes has been created to deal with mirror 
image substances such as Flexizyme for the amino acylation of tRNA with D-amino acid (Fujino 
et al., 2013; Goto et al., 2008) and L-hammerhead ribozyme for hydrolysis of target (L)-RNA 
(Wyszko et al., 2013), the vast majority of enzyme function space of mirror image molecules is 
still vacant. Following the symmetry, one could imagine these catalysts should exist in mirror 
space, which has been proved by the observation that chemically synthesized D- and L-HIV1-
proteases cut their corresponding D-and L-substrates reciprocally (Milton et al., 1992). This 
leads us to focus on possible ways of building D-amino acid (D-aa) containing protein.  
Ribosomal incorporation of D-amino acids into peptides 
The most widely used method for protein production is by cloning the corresponding 
gene into E. coli and utilize the translation system to express it. In E. coli cells, protein is made 
principally by ribosomal translation of a mRNA template. This translation system is superior to 
chemical synthesis in several aspects: first, materials required are simple, one only needs a 
proper strain, a plasmid carrying the gene coding for target protein, and proper media; second, it 
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is easily programmable and with high fidelity with error rate between 10-3–10-4 (Kramer and 
Farabaugh, 2007); third and most importantly, it can make functional protein under physiological 
condition in various scales and throughputs both in vivo and in vitro. In addition, E. coli. protein 
synthesis system has been well studied and documented, one could even artificially reconstitute 
it from individually prepared principal components (Shimizu et al., 2001). However, as the core 
function of cell reproduction, it is not surprising to find that along this translation system, 
mechanisms have evolved to block the incorporation of D-amino acid almost in every move 
(Ahmad et al., 2013). Quoted from an all-encompassing biochemical study on D-tyrosine’s mis-
incorporation (Yamane et al., 1981): 
 “The maximal selectivity that might be realized would include factors of 
25 for aminoacylation (Calendar & Berg, 1966a,b), 25 for ternary complex 
formation, 10 for EF-Tu•GTP-promoted binding, and 5 for peptidyl transfer, a 
total discrimination factor greater than 104. Despite this formidable barrier to 
incorporation of D-tyrosine from racemic mixtures, the partial selectivity of the 
pathway allows the incorporation of D-tyrosine at an appreciable rate if no L-
tyrosine is present, as the work of Calendar and Berg has shown” 
In brief, besides the action of D-amino acid oxidase and D-aminoacyl-tRNA deacylase, 
there are three places where D-amino acids are discriminated from L-amino acids in the core 
translation machinery: aminoacylation of tRNA by aminoacyl-tRNA synthetase (aaRS), 
formation of ternary complex with EF-Tu-GTP as well as its delivery to ribosome, and the 
ribosome’s acceptance and catalysis of peptide-bond formation. Since the existence of 
exceptions (Yamane et al., 1981) of the aaRS and EF-Tu recognition, we will address these 
barriers first before considering ribosome’s involvement and discuss our approaches to overcome 
them. We began with a survey on amino acylation specificity of all 20 aaRS toward D-aa, and 
then compare the chemical-acylation method and the recent ribozyme-catalyzed acylation 
method. Next, we tested the overall effect of EF-Tu’s binding to D- or L-aa-tRNAs, based on 
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different tRNA backbones as well as the choice of codon used (Smolskaya et al., 2013). Doi 
reported that mutations in the amino acid side chain accommodating pocket of EF-Tu could 
enhance the ternary complex formation and delivery of unnatural aa-tRNA into ribosome (Doi et 
al., 2007). We applied Doi’s strategy to make several EF-Tu mutants with bulky residues 
mutated to alanine in order to create room for D-aa side chain. There are two aspects of 
optimizing EF-Tu pocket: the direct one is to improve its binding affinity toward D-aa-tRNA, 
and the second is to confer D-aa-tRNA protection from hydrolysis (Yamane et al., 1981).   The 
ultimate goal of this part of work is to improve the chance of D-aa-tRNA being delivered to 
ribosome.  
Next, we focused on ribosome engineering. It has long been argued that E. coli ribosome 
can catalyze peptide bond formation with D-amino acid. Early evidence of ribosomal 
incorporation of D-aa (Yamane et al., 1981) was based on dipeptide formation assay, which has a 
pitfall that background reactions might contribute significantly to the assay readout. In 1991, 
Bain et al. demonstrated that in an amber-codon suppressing read-through assay, D-
phenylalanine incorporation was not detected compare to glycine (Bain et al., 1991). Later on, 
similar experiment by Schultz groups showed no incorporation of D-alanine while α,α-dimethyl-
amino acid does incorporate at 20% efficiency comparing to L-alanine (Ellman et al., 1992).  In 
2003, Dedkova et al. showed (Dedkova et al., 2003) above-background signal of D-methionine 
and D-phenylalanine incorporation  and create several mutants with enhanced D-aa incorporation. 
However, these read-though experiments were performed in cell lysate and no further validation 
is reported regarding the residue actually incorporated. With the success on reconstitution of 
protein synthesis system in 2001 (Shimizu et al., 2001), this question was revisited but remained 
controversial. Tan et al. reported in 2004 that in a tripeptide fMet-(D/L-aa)-Glu synthesis system 
ǚ9 
 
with only ribosome, initiation factors, elongation factors and chemical acylated D-aa-tRNA, the 
signal of tripeptide corresponding to a D-Ala incorporation was turn out proved to be L-Ala by 
comparing its HPLC trace with standards (Tan et al., 2004).  On the other hand, using flexizyme 
to load all 20 D-aa onto tRNAs, Fujino et al. has shown that in purified translation system 
(commercialized as PURE system) several D-amino acids such as Ala, Ser, Cys, Met, Thr, His 
and Phe can easily be incorporated to peptides (Fujino et al., 2013). They used MALDI-TOF 
mass spectrometry to validate the identity of corresponding incorporated amino acid. However 
the L-aa may contaminate the D-aa starting material, since mass spectrum doesn’t tell the 
difference between D- and L-configurations. In order to avoid this controversy, we decide to first 
develop an assay which is not only sensitive enough to detect the amino acid incorporated when 
at low efficiency but can also distinguish D- or L-configuration. We found the classical amino 
acid analysis method could be of great value if coupled with the use of HPLC and chiral 
fluorescence auxiliary reagents. We demonstrate this method by proving the incorporation of D-
Ala.    
Mutagenesis and selection of ribosome for the ability to incorporate D-amino 
acid consecutively 
Despite several debatable papers reporting single D-amino acid incorporation, 
incorporation of multiple D-amino acids in a row is never reported. Fujino’s data confirmed that 
wild type ribosome doesn’t incorporate D-amino acids consecutively, and a spacer of at least two 
L-amino acids is required to have the second D-amino acid be taken into the polypeptide chain 
(Fujino et al., 2013). A single incorporation of D-amino acid in the middle of protein would 
require two successive reactions, one is its attachment to the previous unit and the other is to the 
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unit after it. Di- and tripeptide synthesis study in the Cornish lab indicates that although D-aa at 
A-site could react at comparable yield to that of L-aa, a large fraction of ribosome PTC is stalled 
when elongating D-aa-tRNA entered P-site (Englander, 2011). Mechanistic study by Rachael 
Green’s group excluded direct participation of ribosome RNA residues in the pepidyl transfer 
(PT) reaction between peptidyl-tRNA and aa-tRNA, but found that the 2’-OH of A76 of 
peptidyl-tRNA is critical (Weinger et al., 2004; Youngman et al., 2004). Since the determination 
of high-resolution crystal structure of ribosome with several aminoacyl and peptidyl-tRNA 
analogues, several ab initio computation works have been done to elucidate the catalytic 
mechanism in detail. It is now known that the attack of α-amine of aa-tRNA to carbonyl in 
peptidyl-tRNA forms the rate-limiting transition state (TS), and two water molecules present in 
close proximity to this substrate transition state play critical roles in the following stage: one 
mediates proton shuttling from 2’-OH to 3’-O– leaving group in A76 of peptidyl-tRNA; the other 
stabilize the negative charge on the ester carbonyl oxygen in TS (Trobro and Åqvist, 2005; 
Wallin and Åqvist, 2010). It is interesting that in this TS, the amide on the preceding pepidyl unit 
also form hydrogen bonding with ammonium of aa-tRNA and the second water molecule, which 
suggests it might also contribute to the stabilization of TS. This view matches the observed lower 
incorporation efficiency when initiated with N-methyl aa-tRNA (Goto and Suga, 2009), and 
could also explain why bacterial translation has evolved to initiate with formylated amino acid. 
However, the presence of proline and the successful initiation with acylated-D-aminoacyl-tRNA 
in the same paper by Goto et al. suggest that this amide stabilization is probably dispensable.  
Although mechanistic studies suggests that none of the nucleobases in ribosomal RNA (rRNA) 
seems to be indispensable either, most previous sequence mutagenesis attempts on this core 
region, e.g. A2451, U2506, U2585, A2602 or other bases around PT center, yield severely 
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diminished activities even with single mutation. As we sought to relax the substrate specificity of 
ribosome to both D- and L-amino acid, we realized that saturated mutagenesis approach would 
leave vast majority of the library being non-active and mutants closely resemble to wild type 
sequence always stand out in both control and experimental group. Therefore, in the subsequent 
attempt we enlarge the region to mutate but lower the mutagenesis rate, hoping that mutants will 
have more balanced level of activities. We also notice that in several regions around peptide 
transfer center, rRNA is packed as loop or coil instead of complementary stem, so changing the 
crowdedness might impact as well as swapping specific inter-base hydrogen bonding network.  
Taken these ideas together, we create mutated sequences by scripts with predefined rate of 
insertion, deletion or base change, and exploit the recent technology of massive parallel 
oligonucleotide synthesis to build mutants. The mutant libraries are expressed in vivo, and 
selected in vitro to read-through codons corresponding to D-aa-tRNA supplied.  Several 
interesting surviving mutants after twelve rounds of selections are collected and characterized 
individually. 
Non-ribosomal peptide and polyketide synthesis 
Although D-aa is excluded from principle protein translation system, it is a commonly 
used substrate in non-ribosomal peptide and polyketide synthesis (PKS) pathways. Resembling 
to peptidyl transfer carried through peptidyl adenosine-3’-O-ester, acyl-transfer in these 
pathways is carried through a thiol on phosphopantetheine group. The difference is that in ketide 
synthesis, the nucleophile is an enolate instead of an amine. Although non-ribosomal polyketide 
/polypeptide synthesis shares similar chemical reactions as ribosomal peptide synthesis, it works 
in an assembly line fashion in which each enzyme only catalyzes one specific residue’s addition 
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or modification reaction (Ferrer et al., 1999; Gindulyte et al., 2006). This makes it more difficult 
to program polyketide synthesis system than ribosome system.  For example, genetic engineering 
of the PKS pathway, has a record of building over 50 variants of 6-deoxyerythronolide B (DEBS) 
(Xue et al., 1999). However, it is only in a few systems like DEBS that we know thorough 
information about the domain DNA sequences and their spatial orientations in the modules that 
lead to the consecutive processing, where we could then rationally engineer the pathway 
(Weissman and Leadlay, 2005). Even with this knowledge, this method is found to be extremely 
inefficient, since the inter-module interactions and dynamics are still largely unclear. Since PKS 
has broad substrate category, we wonder if we can transplant the polyketide synthesis unit to 
ribosomal translation system to collect the merits of both.  Here, we report the synthesis of a 
tRNA with thiol at 3’-terminus, starting with the synthesis of dinucleotide pdCpdA-3-SH, and 
the preliminary observation on its property toward ribosomal polyketide synthesis.  
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Chapter 2: From D-amino acid to D-aminoacyl-tRNA and its 
incorporation to peptide through EF-Tu binding 
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Summary 
We examined three different methods to charge D-amino acid onto tRNA: by aaRS, by 
flexizyme and by chemical synthesis. Among 19 E. coli aaRSs, only three show low but 
measurable activity toward corresponding D-aa.  Comparing to flexizyme system, chemical 
acylation required more labor-intensive synthetic work, but more handy in daily translation assay 
once reagents are available. We also examined several approaches to increase D-aa incorporation, 
effective ones including optimizing the tRNA backbones and relaxing EF-Tu aa-tRNA binding 
pocket. We used read-through assay and develop chiral HPLC method to validate D-amino acid 
incorporation.    
Introduction 
In order to investigate ribosomal incorporation of D-amino acid into peptide, the first step 
would be to build D-amino acid charged-tRNAs. In 1978, Hecht S. et al. showed first example of 
chemical acylation by ligating chemically acylated P1,P2-bis(5’-adenosyl)diphosphate to tRNAs  
without 3’-A (tRNA-C-C-3’OH) (Hecht et al., 1978). This approach was later modified and 
popularized by Noren C. et al. in 1989 by the ligation of acylated pCpA dinucleotide (later 
substituted by pdCpA) to tRNAs without 3’-CA dinucleotide (tRNA-C-3’OH). This strategy is 
applicable to any amino acid. In vitro transcribed, unmodified tRNAs are often used for the 
ligation, due to both the difficulty to specifically remove 3’-dinucleotides in native tRNAs and 
the lack of efficient method to purify individual tRNA isoacceptor. Application of in vitro 
transcribed tRNA has its potential constrain as well, because it lacks modifications which present 
on naturally produced tRNA, which will affect its anticodon•codon interaction and likely its 
binding to EF-Tu or ribosome (Björk, 1996).  
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Recently, Suga et al. has developed an in vitro evolved ribozyme capable of acylating any 
amino acid to full-length tRNA (Goto et al., 2011). Although the acylation yields vary from 10% 
to 80% for different amino acid, it allows the use of any tRNA in full-length, without the need to 
remove nucleotides on its 3’-end.  
Our first goal is to incorporate D-amino acid into conventional protein synthesis system, 
in the presence of aaRS, D-amino acid and all cognate tRNAs. Therefore we first assay the 
activity of purified aaRS for their ability to charge D-amino acid onto tRNA. This is to evaluate 
if there is any aaRS could serve as alternative method to load D-aa onto tRNA, and also to 
prevent, if there is such aaRS, the chance of mis-incorporation of D-aa into wrong position when 
undesired. In this chapter, we described an assay for aaRS charging based on the catalytic PPi 
exchange of aaRS upon binding to cognate amino acid and tRNA. We then compare the 
chemical acylation and the flexizyme acylation approach for the synthesis of D-aa-tRNA. We 
constructed several in vitro transcribed tRNAs with different scaffold sequences and anti-codons 
to compare their affinity toward EF-Tu as well as their decoding efficiency. We also compared 
several cell-free protein synthesis conditions in literature to find potential space to improve the 
delivery of non-aaRS acylated, in vitro transcribed tRNAs.      
Results 
Specificity of aminoacyl-tRNA synthetases 
The most direct assay to measure aaRS activity would be to monitor the production of aa-
tRNA (Figure 1a). However, this is complicated by its instability to hydrolysis and the limited 
availability of purified cognate tRNA isoacceptor. In literature, attempt has been made to 
measure the generation of byproduct AMP (Wu and Hill, 1993), by coupling enzymatic reactions 
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to transform it to the diminish of NADH absorbance. However, we have found the signal of this 
assay is barely detectable. Therefore, instead of aa-tRNA, we measure the catalysis of amino 
acid activation step. It is known that this step is reversible, and aaRS catalyze it in both 
directions. A simple way is to start reaction with ATP and 32PPi and then measure the production 
of 32P-ATP over time (Eigner and Loftfield, 1974). In order to avoid the use of hazardous 
radioactive isotopes, we adapt the strategy developed by Roy et al by using AMPNP, an ATP 
analogue with non-hydrolysable γ-phosphates, with PPi (Roy, 1983), and detect the generated 
ATP by luminescence assay (Figure 1b).  
 
Figure 1.(a) aaRS catalyzed synthesis of tRNA. (b) aaRS activity measured by PPi exchange 
coupled ATP reading by Luciferase assay. 
We set up amino acylation reaction with 10-50 nM of aaRS and 200 µM of AMPNP at 
37°C for 30 min, and luminescence is measured right after the solution is mixed with luciferase 
and D-luciferin. A typical data is shown in Figure 2, the specific activity of aaRS toward D- or 
L-amino acid is calculated from relative light units (RLUs) by the fitted polynomial curved from 
ATP standards.  
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Figure 2. Left, the standard curve of ATP concentration versus the chemical luminescence signal; 
right, PheRS of various concentrations are tested against D-Phe or L-Phe for ATP generation from 
PPi and AMPNP. 
We applied this assay to all 20 aaRSs, but only 10 out of 20 shows activities when the 
corresponding L-amino acid presents, they are AlaRS, ThrRS, PheRS, AspRS, AsnRS, HisRS, 
GlyRS, SerRS and LysRS. When higher concentration of aaRS is used (0.5 to 4.0 µM), CysRS, 
TrpRS and ArgRS give detectable but low activities. However, since all 20 aaRS enzymes in 
reconstituted protein synthesis assay work collectively, we suggest the failure of PPi exchange 
might be the rejection of AMPNP substrate by synthetases. Digging back into literature, we 
found that some type I aaRS from Baker’s yeast indeed can’t use AMPNP as substrate (Freist et 
al., 1980). Therefore, we tried to use another analogue, ATPγS instead. ATPγS gives higher 
background in luciferase assay, so higher [aaRS] is required to get significant and distinguishable 
signal from background.  Also, we noticed that GluRS and GlnRS both require un-acylated 
cognate tRNA for the catalysis of PPi exchange (Ravel et al., 1965), so deacylated total tRNA is 
used in the assay of these two synthetases. The summarized result is shown in Table 1 below. 
aaRS Class Assay condition 
Specific activities (Unit/nmol aaRS)* 
L-aa (s.d.) D-aa (s.d.) No aa (s.d.) 
AlaRS Type II (a) 1018 (36.6) n.d. n.d. 
ThrRS Type II (a) 29 (1.9) n.d. n.d. 
PheRS Type II (a) 22 (19.0) n.d. n.d. 
AspRS Type II (a) 249 (48.9) n.d. n.d. 
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AsnRS Type II (a) 128 (15.6) n.d. n.d. 
HisRS Type II (a) 115 (29.5) 1.2 (0.7) 2.2 (3.3) 
GlyRS Type II (a) 142 (64.5) n.d. 2.8 (3.6) 
SerRS Type II (a) 70 (21.0) 0.9 (0.6) 1.4 (4.1) 
ProRS Type II (a) 403 (35.4) n.d. n.d. 
LysRS Type II (a) 758 (188.7) 7.7 (8.2) 8.4 (2.7) 
CysRS Type I (b) 7.9 (8.0) n.d. n.d. 
TrpRS Type I (b) 35.3 (20.4) 20.0 (15.7) 13.0 (2.4) 
ArgRS Type I (b) 11.8 (3.6) 4.0 (1.7) 0.4 (0.1) 
 
ValRS Type I (c) 458.9 (124.4) n.d. n.d. 
IleRS Type I (c) 911.7 (229.2) n.d. n.d. 
LeuRS Type I (c) 200.5 (-) n.d. n.d. 
MetRS Type I (c) 415.3 (144.3) n.d. n.d. 
TyrRS Type I (c) 1228.3 (506.6) 320.2 (82.8) n.d. 
GluRS Type I (c) 10.3 (2.4) n.d. n.d. 
GlnRS Type I (c) 1077.1 (246.2) n.d. n.d. 
Table 1. Summary of specific activities of aminoacyl-tRNA synthetases promoted by cognate L- 
or D-amino acids. Assay condition (a) 200 µM AMPNP with 10-50 nM of aaRS, (b) 200 µM 
AMPNP with 0.5-4.0 µM of aaRS, (c) 200 µM ATPγS with 20-50 nM of aaRS. Specific activities 
is averaged across the range of [aaRS] tested. *1 unit of aaRS exchanges 1nmol of PPi with AMP-
AA to ATP in 30min at 37°C  
In agreement with previous report (Soutourina et al., 2000), we find TyrRS, TrpRS and 
ArgRS have slight to moderate tolerance toward D-form analogue of cognate amino acid. Beside 
these three synthetases, we didn’t detect PPi exchange activity promoted by any other D-amino 
acids. Our assay shows that the L-form amino acids of these three aaRSs, TyrRS, TrpRS and 
ArgRS promote catalysis in about 3-4 times faster. However, Soutourina et al. indicates the 
initial rate of aa-tRNA synthesis with L-form amino acid is about 100 times faster than D-form 
analogue. The difference suggests that the structural requirement in the second acylation step is 
more stringent than the first amino acid activation step. And our assay demonstrated that for the 
vast majority of aaRS, D-amino acids are blocked at the very first stage, so there shouldn’t be 
any concern on toxicity of D-amino acid for cell free protein synthesis application. But on the 
other hand, using aaRS to charge D-amino acid onto tRNA would be very inefficient if the 
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corresponding L-aa is present even for D-aa accepting aaRS. In the next section, we will explore 
two other approaches. 
Non-enzymatic acylation and chemical acylation 
As we are looking for a general method to efficiently load D-aa onto tRNAs, the 
Flexizyme system appears to be a good candidate. It was first published in 1996-2000 as an 
aminoacyl-RNA transferase by Szostak’s lab (Lee et al., 2000; Lohse and Szostak, 1996), is later 
evolved into trans-acting tRNA aminoacylase for cyanomethyl activated L-Phe in 2001 (Saito et 
al., 2001) and generalized to all amino acids in 2006 by placing the ribozyme’s recognition 
moiety on carboxyl-terminus activating group (Murakami et al., 2006).  The general scheme of 
this amino acid activation and transacylation system is shown in Figure 3. 
 
Figure 3. General scheme of Flexizyme mediated acylation of tRNA. Activation step is done by 
SN2 reaction between carboxylic acid and 3,5-dinitrobenzyl-chloride (DBE-Cl) or 
chloroacetonitrile (CME-Cl) or by EDC-coupling between carboxylic acid and chlorobenzyl-thiol 
(CBT). 
The advantage of this methodology is its easy implementation. Chemical synthesis of 
activated amino acid is straight forward. The disadvantage is that amino acid acylation condition, 
i.e. time, need to be individually optimized also the one need to prepare each AA-tRNA 
24 
 
separately. We prepared several activated D-amino acid according to the scheme above and have 
successfully load them on to an amber suppressor tRNA. 
 
Figure 4. Analysis of flexizyme charged tRNA. After acylation reaction, the aa-tRNAs are labeled 
with 7.5 mg/mL of NHS-Biotin in 400 mM Hepes-KOH buffered at pH 8 and then analyzed on 
15% TBE-Urea gel with 0.2 mg/mL streptavidin in loading buffer. Lys(B) denotes D-Lys(Biotin). 
*gel analysis without NHS-Biotin labeling.  
Several standard amino acids work well with flexizymes, such as Gly, D-Ser, D-Leu, D-
Lys, D-Ala and D-His, but there is also a few acylate poorly. Solubility of activated amino acid 
in the aqueous reaction environment is considered the cause of poor reactivity for hydrophobic 
residues (Murakami et al., 2006). This also explains why we observe very low acylation rate of 
the D-Lys(Biotin)-DBE substrate. Murakami et al. claims that the low observed yield by this 
assay is partly due to the deacylation during the NHS-Biotin labeling reaction. Earlier literature 
also stated that aa-tRNA deacylate very fast at pH > 6 conditions, with half-life ranged from few 
minutes to an hour depend on the side chain (Hentzen et al., 1972). To confirm if the low level of 
D-Lys(Biotin)-tRNA observed is due to poor acylation, we duplicate the lane without treatment 
of NHS-Biotin and analyze yield of acylation side-by-side with the NHS-Biotin treated sample. 
As it shows on the last two lanes of Figure 4, the observed yields are about the same with or 
without NHS-Biotin treatment, we conclude that the reaction itself is not efficient in this case. 
According to all published articles from Suga’s group and personal communication with Dr. 
㫈 
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Suga, we learned that besides extending reaction time, which we have done from 8 hours to 72 
hours, there is no simple mean to further enhance efficiency. 
In the next chapter we will describe ribosome mutants screening system which utilizes D-
Lys(Bio) and several other non-proteingenic dialkylamino acid which also acylate very poorly by 
flexizyme system. Therefore, we also establish the chemical acylation in our lab as a 
complement for the flexizyme system with slight modification from (Ellman et al., 1991). As 
shown in Figure 5, the N-protected amino acid is first activated as cyanomethylester and then 
coupled to dinucleotide ‘pdCpA’ at either 2’-OH or 3’-OH. It is not necessary to isolate the 3’-O 
acylated product, since the intramolecule transacylation is rapid and EF-Tu would selectively 
pick up the 3’-O-aminoacyl tRNA (Sprinzl, 2006). The acylated dinucleotides are then ligated to 
in vitro transcribed tRNA without 3’–CA. We use NPPOC as N-terminus protecting group (PG) 
since its convenience to remove (illuminated by 100W hand-held UV-lamp) than traditional 
Nvoc (illuminated by dangerous 1000W Xenon lamp with filter) and 4-pentenoyl (I2 / pyridine 
followed by ethanol precipitation).  
 
Figure 5. Scheme of chemical acylation. N-protected amino acid is first activated as 
cyanomethylester and then coupled to dinucleotide ‘pdCpA’ at either 2’-OH or 3’-OH. The 
acylated dinucleotides are then ligated to in vitro transcribed tRNA without 3’–CA. 
㿸 
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We have found that the NPPOC protected aminoacyl dinucleotides are very stable at pH 
7.4 buffered solutions (no hydrolyzed pdCpA detected), and the T4 RNA ligase mediated 
ligation is generally efficient disregarding what amino acid attached.  To our surprise, when 
same in vitro transcribed tRNAs loaded with same amino acid by each method are subjected to a 
protein synthesis assay, we found the chemical acylated tRNA leads to better yield. Potential 
explanation is that the NPPOC protecting group removed right before translation reaction also 
protects the aa-tRNA from hydrolysis during sample storage and handling. In summary, we have 
built and tested several activated d-amino acid substrates for flexizyme acylation and several D-
aa or α,α-dialkyl-aa-pdCpA for ligation method. They are listed in the table below: 
via Flexizyme   via Ligation  
std. AA non std. AAs  std. AA non std. AAs 
Gly-DBE D-Lys(Biotin)-DBE  Gly-pdCpA N-Biotin-L-Nvl-pdCpA 
D-Ser-DBE Aib-DBE  L-Ile-pdCpA N-Ac-L-Lys(Biotin)-pdCpA 
D-Leu-DBE D-Iva-DBE  L-Ala-pdCpA L-Dap(DEAC)-pdCpA 
D-Lys-DBE D-Phe(N3)-CME  D-Ala-pdCpA D-Dap(DEAC)-pdCpA 
D-Ala-DBE   L-Val-pdCpA Aib-pdCpA 
D-His-DBE   D-Val
1-13C-pdCpA Deg-pdCpA 
D-Asn-DBE  D-Iva-pdCpA 
D-Pro-DBE  
L-Leu-DBE  
D-Thr-CBT  
D-Ile-CBT  
D-Val-CBT  
D-Phe-CME  
L-Phe-CME         
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Table 2. Amino acid building blocks synthesized for mis-acylation in this project. Structures of 
non-standard amino acid are shown. 
Two assays for D-amino acid incorporation and the interaction of aa-tRNA and EF-Tu 
While we building a ribosome selecting system looking for better D-amino acid 
incorporation, we attempted to measure whether the D-aa incorporation through fluorescence gel 
imaging by the use of L-Lys(BODIPY)-tRNALys (commercially available) or D/L-Dap(DEAC)-
tRNA but with no success. Difficulty of incorporating bulky dye moieties is causing low protein 
production already. In order to have identifiable and amplifiable signal of the expressed peptide 
containing in vitro misacylated amino acid, we use western blot to detect the expression of a 
downstream FLAG-epitope after read-through D-aa-tRNA corresponding codon (Figure 6a). As 
for first screening for experiment conditions, this method is sensitive and handy, but with 
potential caveat that the residue incorporated is not the amino acid supplied on aa-tRNA.  In 
order to reduce chance of mis-recognition of endogenous aaRS to supplied aa-tRNA, we reduce 
the template composition and hence the use of aaRSs and amino acids in PURE translation to 
䱸 
28 
 
only six amino acids: Asp (D), Tyr (Y), Lys (K), Trp (W), Met(M) and Leu(L)1. The templates 
we designed contain N-terminus FLAG-tag coding sequence followed by one or two consecutive 
unassigned codons (amber stop codon without RF1 or amino acid codon without aaRS) and then 
a coded stretch of 78-amino acid containing mixed D, Y, K, L, M and W in order to stick read-
through peptide on to blotting membrane.   
fM - D - Y - K - D - D - D - D - K -Xaa1-(Xaa2)-[D/Y/K/M/W/L]78
5'UTR-AUG-GAU-UAC-AAG-GAU-GAC-GAC-GAU-AAG-NNN1-(NNN2)-[mixed codon]78-UAA
codon NNN : ACC, AAC, UCC, UAG
Xaa
anticodon : GGU GUU GGA CUA
Xaa-tRNAanticodon
Body seq. identity :
a)
b)
mRNANNN : AAC UCC UAG -ACC
UAG
LVal-tRNAAsnE2 : +- +- +- +- -
mRNANNN :
Xaa-tRNAAsnE2 :
-
Aib DAla DIva DVal DPhe -
UAG2 UAG-ACC UCC-ACC
LVal-tRNAAsnE2 :
LVal-tRNAAsnE2 :
mRNANNN1-NNN2 :
anti-NNN1
anti-NNN2anti-NNN
-+ ++ +- -+
-+ -+ ++ +-
-
-
UAG
- DAla LAla DVal LValCUA
c)
mRNANNN :
peptideX :
U C A G
U
C
A
tRNACUA Trp G
U
C
A
G
U
C
A
Met G
U
C
A
G
Tyr
Lys
Asp
G
tRNAGGA
tRNAGGU tRNAGUU
Leu
U
C
A
1s
t  
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Figure 6. (a) General read-through assay used in this study, peptide with N-term FLAG-tag is 
expressed followed by one or two unassigned codon NNN and then a stretch of 78mer DYKWLM 
amino acids. The four anticodons-codon pairs are shown on the right and each tRNAanticodon’s 
potential decoding range (including wobble) is shown on the left in codon table. (b) Test of aa-
tRNAanticodon dependent read-through for four codons ACC, AAC, UCC, UAG and three 
consecutive dual codons UAG-UAG, UAG-ACC and UCC-ACC. The presence of band of FLAG-
containing peptide indicate successful read-through of codons by chemically acylated tRNAs. (c) 
Test incorporation of several D, L-amino acids. mRNA with label “−” is a template without 
middle NNN codon and hence full-length peptide synthesis doesn’t require chemically acylated 
                                                     
1 Asp(D), Tyr(Y) and Lys(K) are chosen since they are required for FLAG-tag; Met(M) is needed for translation 
initiation; Trp(W) has intrinsic fluorescence which, although weak, will be used as trace in HPLC purification 
example later; Leu(L) is added to adjust overall peptide hydrophobicity, as well as to reduce DNA coding repetition.  
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tRNA. tRNAAsnE2 is evolved from E. coli tRNAAsn to be orthogonal from all 20 aaRSs (Goto et al., 
2011). All experiments shown in this figure are conducted with12 µM of misacylated aa-tRNAs 
(prepared by chemical acylation) and 2 µM of EF-Tu.  
To find out optimum condition to measure unnatural amino acid (Uaa) incorporation rate, 
we began with the choice of codon for single and consecutive dual incorporation. It has been 
pointed out that the “fourth nucleotide”, i.e. the first nucleotide in the next codon, has significant 
effect on decoding efficiency for UAG suppressor tRNAs in general, with better efficiency for 
codon followed by purines and worse for one followed by pyrimidines (Bossi, 1983; Smolskaya 
et al., 2013). However, although findings from Ayer et al. (Ayer and Yarus, 1986) against 
hypothetical base-pairing of suppressor tRNA U33 to the fourth codon, it suggests that these bias 
are less significant when relatively more efficient suppressors are used. We pick four codons 
ACC, AAC, UCC and UAG to test, and transplant their corresponding anti-codon into an 
orthogonal tRNA evolved by Suga’s group (Goto et al., 2011). The translation reaction is carried 
out with only six amino acids, aaRSs and deacylated E. coli total tRNA. On the left panel of 
Figure 6b, the read-through of single ACC, UCC and UAG are mainly depend on the supplied 
aa-tRNA, and their decoding efficiencies are at the same level. Since there is significant 
background read-through of AAC codon, we leave it out of our candidate list. Notice that the 
UAG codon also has low but not negligible background read-through. Therefore, in later section 
I will describe a 2nd assay we developed to verify the identity of the incorporated residues to 
prevent misinterpretation. On the right panel of Figure 6b, when testing for two consecutive 
read-through events, the overall decoding yield of UAG-AAC surpasses the yield of UAG-UAG, 
agreed with the codon context effect mentioned above. The decoding of UCC-ACC is in between 
UAG-UAG and UAG-ACC, but to our surprise, it seems that aa-tRNAGGU targeting the ACC 
codon can also read UCC and yield full-length peptides when aa-tRNAGGA is not present. For the 
sake of simplicity, we use only UAG-UAG and UAG-ACC in downstream experiment.  When 
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we applied this assay to a few D- or L-aas, we could only see incorporation of L-Val. Although 
L-Val-tRNA has one of the longest half-life toward hydrolysis in neutral pH solution, i.e. 60 
mins versus Ala-tRNA’s 6 mins (Hentzen et al., 1972), we found neither increasing initial 
concentration of L-Ala-tRNA nor adding multiple “booster doses” of L-Ala-tRNA during the 
course of translation helps to improve yield significantly.    
This finding leads us to ask that whether the difficulty of incorporating L-Ala is the result 
of its aa-tRNA’s poor interaction with EF-Tu. We also concerned if there is a competitive 
binding of aa-tRNAs resulting from the limiting amount of EF-Tu in the PURE translation 
system we used. In vitro experiment (Asahara and Uhlenbeck, 2002; Louie et al., 1984) shows 
that 21 different E. coli unmodified tRNA body sequences, when all acylated with same amino 
acid such as L-Val, display a wide range of binding affinities to EF-Tu from KD = 0.5 nM for 
LVal-tRNAGlu to 310 nM for LVal-tRNATyr. Also, this trend is modulated by the corresponding 
acylated amino acid, i.e. the weaker binder tRNATyr are linked to stronger binding promoter L-
Tyr and vice versa for tRNAGlu, in order to have all endogenous aa-tRNA shared similar affinity 
to EF-Tu. One the other hand, when the same tRNA is loaded with different L-amino acids the 
range of affinity toward EF-Tu spans at least 80-fold (Dale et al., 2004). The list of experimental 
dissociation constants in these literatures are reorganized in the table below: 
Xaa-tRNABody seq. KD [nM] Val-tRNA
Body seq. KD [nM] 
∆G° 
[kcal/mol] Xaa-tRNANNN(Xaa) 
KD 
[nM] 
∆G° 
[kcal/mol] 
Glu-tRNAGlu2 43.6 Val-tRNAGlu2* 0.5 -11.7       
Asp-tRNAAsp1 28.3 Val-tRNAAsp1* 1.9 -11.0 Asp-tRNAYFA2 >150.0 < -8.6 
Gly-tRNAGly3 11.4 Val-tRNAGly3 2.8 -10.7 Gly-tRNAYFA2 62.0 -9.1 
Thr-tRNAThr 16.1 Val-tRNAThr3 4.0 -10.5 Thr-tRNAYFA2 15.0 -9.9 
Ala-tRNAAla1B 28.6 Val-tRNAAla2 4.3 -10.5 Ala-tRNAYFA2 100.0 -8.8 
Cys-tRNACys 13.6 Val-tRNACys 21.0 -9.6 
Leu-tRNALeu4 24.7 Val-tRNALeu1 23.0 -9.5 
Met-tRNAMet 10.6 Val-tRNAMet 33.0 -9.4 Met-tRNAYFA2 17.0 -9.8 
Pro-tRNAPro 12.6 Val-tRNAPro3 34.0 -9.3 Pro-tRNAYFA2 15.0 -9.8 
Phe-tRNAPhe 13.8 Val-tRNAPhe 48.0 -9.2 Phe-tRNAYFA2 11.0 -10.1 
Lys-tRNALys1 43.5 Val-tRNALys 53.0 -9.1 Lys-tRNAYFA2 35.0 -9.4 
Arg-tRNAArg2 26.5 Val-tRNAArg2 54.0 -9.1 Arg-tRNAYFA2 17.0 -9.8 
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Ser-tRNASer 15.9 Val-tRNASer1* 61.3 -9.1 
Asn-tRNAAsn 10.6 Val-tRNAAsn* 88.3 -8.9 
Val-tRNAVal1 92.0 Val-tRNAVal1 92.0 -8.8 Val-tRNAYFA2 17.0 -9.8 
Ile-tRNAIle 27.0 Val-tRNAIle1 110.0 -8.7 Ile-tRNAYFA2 8.1 -10.3 
Trp-tRNATrp 9.9 Val-tRNATrp* 183.6 -8.5 Trp-tRNAYFA2 3.6 -10.7 
Gln-tRNAGln 5.7 Val-tRNAGln2 250.0 -8.3 Gln-tRNAYFA2 1.9 -11.1 
Tyr-tRNATyr2 15.7 Val-tRNATyr2 310.0 -8.1       
  LTyr-tRNATyr  50.0 -9.2 
        DTyr-tRNATyr  1200.0 -7.5 
Table 3. Dissociation constant of aa-tRNA and EF-Tu•GTP complex (column 4, 5, 7, 8) were re-
presented from (Asahara and Uhlenbeck, 2002; Dale et al., 2004); L- or D-Tyr-tRNATyr data are 
from (Yamane et al., 1981). For Xaa-tRNABody seq. (column 2), KD of Phe and Leu are obtained 
first from the relative KD ratio of Val/Phe and Val/Leu4 from (Louie et al., 1984), and then we 
refer to KD of Phe and Leu for all rest L-aas. When same amino acids are acylated to different 
tRNA body sequences, the range of KD spans ca. 600-fold, and when various amino acids are 
acylated to same tRNA, the range of KD spans at least 80-fold based on the 13 tested amino acids. 
The L-Tyr acylated tRNATyr binds to EF-Tu•GTP 25-fold stronger than D-aminoacylated version. 
Notice that the dissociation constants are measured at 0 °C, the same constant at 37 °C is 6-10 
folds higher, calculated using ∆G° = -RT ln (1/KD).  *Data converted from the measured KD of 
Phe-tRNABody seq..    
In our experiment, the tRNAAsnE2 seems to be one of the very poor binders as its ancestor 
tRNAAsn, since most of the residues in contacted with EF-Tu are shared between the two. If so, 
plus if the total amount of endogenous aa-tRNAs exceeds available EF-Tu during in vitro 
translation, then even in the case of L-amino acid, linearly increase of the concentration of 
misacylated aaweak-tRNAweak will have only little to negligible effect on equilibrium 
concentration of ternary complex [EF-Tu•GTP•aa-tRNA]. This is similar to what we saw. To 
investigate whether our PURE translation set up is sub-optimized, we summarized the relative 
amount of EF-Tu and level of aaRS-maintained aa-tRNAs in literatures which is demonstrating 
unnatural amino acid incorporation in cell free protein synthesis below (Table 4):  
Year, Lab Translation system 
[EF-Tu], 
µM 
[aa-tRNAaaRS], 
µM 
[aamis-tRNA], 
µM 
- E. coli cell (mid-log phase) ca. 100*
a ca. 100*b - 
1992-2013 
Schultz P. & Hecht S. Cell extract ca. 25*
c ca. 6.4 12 
2001-2013 
Ueda T. 
Purified comp. 
(all 20 aaRS) 2*
d ca. 53 20 
2007-2013 
Suga H. 
Purified comp. 
(with 4 aaRS) 10*
e ca. 13*f 25-600 
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2014 
This study 
Purified comp. 
(with 6 aaRS) 2, 25*
g ca. 18*f 12-24 
Table 4. Comparing the relative amount of EF-Tu and level of aaRS-maintained aa-tRNAs in 
literatures and our assay. *a ref. from (Pedersen et al., 1978); *b ref. of total tRNA concentration is 
from (Dong et al., 1996), and ref. of total aa-tRNA concentration is from (Jakubowski and 
Goldman, 1984); *c ref. from (Ellman et al., 1991); *d ref. from  (Shimizu and Ueda, 2010); *e ref. from  
(Goto et al., 2011); *f calculated based on total tRNA used in reaction times fraction of isoacceptors will be 
charged by the supplied aaRS; *g 2 µM EF-Tu is used in experiment shown in Figure 6, 25 µM is used in 
all subsequent experiments after optimization. 
In our previous assay shown in Figure 6, we used 2 µM of EF-Tu and 53 µM of tRNA (ca. 
18 µM been acylated by the 6 supplied aaRS) in the translation system based on Ueda’s protocol, 
which now seems to be an adverse condition for incorporating LAla-tRNA, an acyl-ester that 
promotes aa-tRNA•EF-Tu interaction poorly. In fact, L-Ala acyl ester might be worse in 
promoting EF-Tu association than some good ones in D-form such as D-Tyr, if assuming L-to-D 
change will invariably reduce affinity by 25-fold. This suggests that the previously perceived 
trouble on incorporating D-aas might to a great extend be the same one troubling LAla here.  
Therefore, we examine if increasing either [EF-Tu], [LAla-tRNAAsnE2] or both could alleviate the 
problem. We first investigate the effect of [EF-Tu] versus peptide production without involving 
Xaa-tRNA (Figure 7a) to find highest tolerable [EF-Tu]. We found that the best expression is 
achieved between 10-25 µM of EF-Tu, and the yield drops above that. However, at 35 µM of 
EF-Tu one could still get ca 84% of yield comparing to the maximum yield.  
 Ԓ
33 
 
 
Figure 7.  (a) Protein synthesis versus [EF-Tu] used, in searching for the highest tolerable [EF-Tu]. 
(b) Increasing either [LAla-tRNAAsnE2] or [EF-Tu] or both improves incorporation rate. Except 
when [LAla-tRNAAsnE2] is as low as 8 µM, increasing [EF-Tu] seems to have no effect. Around 13 
µM of endogenous tRNA are used. (c) Various tRNA backbones with CUA anticodon are tested 
for the incorporation of Gly and DPhe, with 24 µM of chemical acylated aa-tRNA and 25 µM of 
EF-Tu.  Good tRNA body such as Glu2 allows observable DAA incorporation. mRNA with label 
“---” is a template without middle NNN codon and hence full-length peptide synthesis doesn’t 
require chemically acylated tRNA. 
In Figure 7b, we run reactions with 12 µM of total aaRS-maintained [aa-tRNA], and test 
whether or not the excess EF-Tu (15µM EF-Tu minus 13 µM for endogenous aa-tRNA and 2 µM 
left) would promote incorporation by raising EF-Tu-bound LAla-tRNAAsnE2 in equilibrium. The 
result is somewhat inclusive that while increasing [EF-Tu] does improve yield when 16 µM of 
aa-tRNA is used, it has no obvious effect when 8 µM of aa-tRNA is used.  But nonetheless, if 
increasing each’s concentration of the two associating partners could both promote aa-tRNA 
delivery, then it is reasonable to expect that tuning up the affinity between the two would do the 
same trick. 
Accordingly, we build tRNAs with body sequence taken from the top list of strong 
binders 2 , and test if they were able to deliver non-preferred amino acids better. Although 
                                                     
2 The list on Table 3 includes Thr2, Ala2, Glu2, Asp1 and Gly3. We didn’t take Asp1 since we have AspRS during 
translation, and we use GlyRS to make peptide for the HPLC assay which will be described later.  
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orthogonality of tRNAAsnE2 toward all E. coli aaRSs is usually a desired property, this is not 
likely to trouble us since we only use 6 aaRS at this stage. In the long term, more Xaa would be 
brought in by non-enzymatic acylation method in order to use as much codons as possible, and 
aaRS would be slowly phased out eventually. As shown in Figure 7c, when these tRNAs are 
acylated with Gly, which is as poor as Ala in promoting tRNA-EF-Tu binding, DPhe or used as 
free 3’-OH, we found the Glu2 backbone shows superior capacity to incorporate both Gly and 
DPhe while none of the other tRNAs can do either one.  
Mutagenesis study of EF-Tu for enhanced D-AA delivery capacity  
The striking bias of EF-Tu on tRNA backbones in the incorporation of chemically 
charged aa-tRNA reminds us that it could also play role as significant as ribosome in 
discriminating D-amino acid. The previous biochemical data has shown its 25-fold preference 
for LTyr versus DTyr-tRNATyr, and the binding of DTyr-tRNATyr to EF-Tu doesn’t protect it from 
hydrolysis, which indicates DTyr-acyl ester must adopt a different conformation than L-form 
when bound. In crystal structure (PDB ID: 1OB2) of EF-Tu in ternary complex with Phe-
tRNAPhe, the region surrounding amino acyl Cα-hydrogen, where D-side chains would locate, is 
well packed, which suggests there is a steric determinant applied for all amino acid substrates.  
To avoid complication on considering how each D-side chains of Daa-tRNA would affect their 
association with EF-Tu, and also in attempt to restore EF-Tu’s ability to protect Daa-acyl ester 
from hydrolysis, a preliminary mutagenesis study was performed on EF-Tu. 
We pick eight residues on EF-Tu that are closest to the D-side Cα proton of aa-tRNA, in 
an ‘alanine scanning’ fashion, each mutant contains one bulky residue mutated to alanine among 
these eight sites, with the hope to relax the packing in this region. Doi Y. et al. has applied the 
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same strategy to successfully create mutants capable to tolerant amino acid with bulky side 
chains such as L-1-Pyrenylalanine or DL-2-anthraquinonylalanine (Doi et al., 2007).  These 
residues are D216, V226, V227, T228, V258, N273, V276 and L277. 
   
Figure 8. Illustration of eight EF-Tu residues around Cα-H of LPhe-tRNA been mutated to Ala in 
this study. Cartoon in grey is EF-Tu; side-chains of residues been mutated are plot as stick in cyan; 
Phe is plotted as stick in pink. Structure is generated based on PDB ID: 1OB2 (unpublished data). 
These mutants are cloned and purified with C-terminus His6-tag, as the wild-type. When 
their activities on expressing normal peptide are tested, to our surprise, all mutants promote 
translation similarly (Figure 9a). When assaying their abilities to incorporate artificially charged 
aa-tRNAs, mutant V276A shows significant improvement on yield while others perform the 
same as wild type. It is interesting that V276 has no direct contact with amino acid on aa-tRNA 
(Figure 9c), and it not only promotes D-aa incorporation but also L-aa such as Gly. Based on the 
crystal structure, V276 is not the residue (9.6 Å) having direct contact with aa-tRNA among the 
8 residues mutated in this study, this effect is unexpected, as it suggests that there is still room to 
improve on efficiency of the aa-tRNA•EF-Tu•ribosome system although it has been naturally 
evolved for 3.5 billion years since the cyanobacteria. We are building more mutants with more 
Ala substitutions around V276 and also screen the region surrounding the L-side chain of 
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aminoacyl ester instead of D-side, such as H66, F261 and M260, since (Yamane et al., 1981) 
proposed D-aminoacyl ester bind to EF-Tu with different conformation than L-form. 
D2
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Figure 9. (a) Assay translation activities of 8 EF-Tu mutants on normal peptide. All mutants 
perform at similar level as wild-type. (b) Comparing wild-type EF-Tu and mutant V276A on their 
capacity to promote incorporation of artificially charged aa-tRNAs. mRNA with label “---” is a 
template without middle NNN codon and hence full-length peptide synthesis doesn’t require 
chemically acylated tRNA. (c) Distance between EF-Tu residue V276 to Cα of LPhe-tRNA and 
their context.  Structure is generated based on PDB ID: 1OB2 (unpublished data).  
HPLC assay to validate D-amino acid incorporation 
Western blot of D-aa-tRNA dependent read-through peptide expression is the first 
evidence we observed. In order to confirm it is D-amino acid, not trace amount of enantiomeric 
L-form impurity instead, we design a second assay based on HPLC to check their identity. In this 
assay, as shown in Figure 10a below, mRNAUAG-ACC containing two unassigned codons is used 
to express peptideXY, which is isolated by FLAG affinity purification and further clean up by 
HPLC. They are then acid hydrolyzed to yield individual amino acids3, derivatized by a chiral 
auxiliary group (+)-1-(9-Fluorenyl)ethylchloroformate (FLEC) and  analyzed by HPLC. We 
                                                     
3 To prevent complication of signal and to reduce noise, we didn’t add any additives in 6N HCl during hydrolysis 
such as phenol or thiol. Therefore Met, Tyr and Trp are not recovered, as they will be oxidized during hydrolysis. 
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applied this method to DAla and DPhe by putting them onto tRNA corresponding to UAG codon. 
After translation and FLAG affinity purification, on HPLC, we found that peptides with or 
without Xaa incorporation have different retention time, which is small in the case of D/L-Ala 
but larger for D-Phe. We collect these fractions and performed hydrolysis and derivitization. 
HPLC trace of labelled amino acid hydrolysates from peptideL-Ala, peptideD-Ala are compared with 
labelled standard L-amino acids plus DAla and DPhe.  Contrasting the trace of peptideL-Ala, 
peptideD-Ala, DAla signal is only presented in peptideD-Ala hydrolysate, which indicates that it comes 
from the peptide expressed but not from racemization of LAla during acid hydrolysis. 
Unfortunately, the HPLC analysis of peptideD-Phe is inconclusive due to overwhelming 
protein contamination, so we are currently looking for additional purification strategy to resolve 
this issue.    
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Figure 10. HPLC assay of incorporated amino acid. (a) Template contains codons assigned to 
artificially charged aa-tRNA are placed after FLAG-tag for affinity pull down. The eluted peptides 
are then purified by HPLC and hydrolysis in 6N HCl to individual amino acids. Amino acids are 
then derivatized by chiral auxiliary (+)-1-(9-Fluorenyl)ethylchloroformate and analyzed by HPLC 
with standard C18 column. Notice we utilize only UAG codon in this experiment here. (b) HPLC 
trace of three affinity purified peptides. The peak on the left corresponds to FLAG peptide used 
for elution. Peptides with incorporated D/L-Ala or D-Phe might share close retention time to those 
from peptides without any incorporation. (c) Structure of (+)-1-(9-Fluorenyl)ethylchloroformate (d) 
HPLC trace of (+)-FLEC labelled amino acid hydrolysate from peptideL-Ala and peptideD-Ala. Trace 
of standard amino acid mixture plus DAla and DPhe are shown on the bottom.  
Discussion 
In this chapter we discussed two factors discriminating D-amino acid from L-amino acid 
in bacterial translation system, amino acyl tRNA synthetases (aaRS) and elongation factor Tu 
(EF-Tu). We began with the survey on the substrate specificities of all 19 L-aaRSs, in order to 
assess the possibility to use endogenous aaRS to load D-aa onto tRNA. The result confirmed the 
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literature report that only TyrRS, TrpRS and ArgRS shows low but measurable activity toward 
corresponding D-aa. Therefore we moved to chemical acylation and Flexizyme acylation, and 
several substrates are prepared for both strategies. When we first used these artificially charged 
tRNA to incorporate Xaa into peptide, we have problems even on some proteingenic L-aa such 
as LAla. Therefore we took several approaches to address this issue all surrounding the same 
principle: increasing the affinity between EF-Tu and aa-tRNA. We tested if different codon 
affects yield, and found that it does not with the presence of single codon, but the yield is slightly 
compromised when successive dual UAG codon appears. We tested if tRNA backbone 
sequences affects yields, and it did. And we also found an EF-Tu mutant V276 that could further 
enhance the overall translation yield, with mechanism to be investigated.  
The aa-tRNAs used for translation in this chapter are all chemically acylated, since it is 
operationally convenient once we have aa-pdCpAs available. The in vitro transcribed tRNA used 
for ligation has a 5’-GTP structure instead of the native 5’-GMP.  We have compared the effect 
of 5’-GTP versus 5’-GMP and found that it does not compromise incorporation yield if not 
facilitate the process (data not shown). One possible explanation is that 5’-GMP tRNA 
complicates ligation reaction, and so following-up experiment is proposed to reexamine this 
effect with flexizyme charged tRNA. 
To our surprise is that at lower concentration of LAla-tRNAAsnE2 (8 µM) and EF-Tu (10 
µM), increasing [aa-tRNA] has more prominent effect then increasing EF-Tu. Possible 
explanation is that increasing amount of [EF-Tu] increases EF-Tu•GTP ternary complex 
formation of other weak-binding aa-tRNA, therefore the overall probability of delivery to 
ribosome is not increased much.  
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However, we found that changing tRNA backbone sequences has more prominent affects 
than tuning concentration of each component. Non-preferred amino acids, such as Gly, LAla or 
DPhe, could acquire moderate incorporation when acylated to a preferred tRNA backbone. 
However, when considering to incorporate more than one artificially charged amino acids with 
very different affinity toward EF-Tu, i.e. Xaa and Yaa, adjustment on the ratio of [Xaa-
tRNA]/[Yaa-tRNA] is necessary to balance each ternary complex’s concentration. Otherwise the 
weaker aminoacyl-tRNA would incorporate poorly. High concentration of the aa-tRNA with 
lower affinity is required to form adequate amount of ternary complex, since raising [EF-Tu] too 
much would hurt translation yield, as shown previously. But this is very inefficient and wasteful 
since the vast majority of weak aa-tRNA will be unbound, and they hydrolyze quickly 
comparing to time scale of translation reaction. Given that all other D-amino acids have lower 
incorporation rates than DPhe (Fujino et al., 2013), it would be desired to have EF-Tu tolerating 
D-aa as well as L-aa. And then pairing more preferable tRNA backbone with weak D-aa could 
be employed along with Glu2 to modulate more than one D-amino acids, without using large 
excess of particular aa-tRNA wastefully. 
Materials and Methods 
Preparation of amino acyl-tRNAs 
Procedures to synthesis of CME-, CBT- and DBE-activated amino acids are adopted 
from (Murakami et al., 2006). Procedure for the synthesis of pdCpA are from (Ellman et al., 
1991), NPPOC protection from (Bhushan et al., 2003). Identity and purity of all substrates are 
confirmed by either HRES-MS, NMR or both.  
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In vitro transcriptions of tRNA, dFx or eFx are done as follow: prepare 300 µL mixture 
of 4mM NTPs, 0.5 U/µL Murine RNase Inhibitor (New England Biolab Inc.), 10mM DTT, 100 
µg/mL T7 RNA polymerase, 125 µg/mL inorganic pyrophosphatase, 1x T7 transcription buffer 
(contains 40mM Tris-HCl pH 8.1, 20mM MgCl2, 0.1 % Triton X-100, 30mM Spermidine and 
500 µg/mL BSA) and optional 10 % DMSO (for tRNAGlu2 synthesis) and incubate at 42 °C for 
2.5hr. After that, 200 µL mixture of same components except with 10mM NTPs, 30mM MgCl2 
and 20 µg/mL T7 RNA polymerase is added into previous reaction, and further incubate at 38 °C 
overnight. The product is washed with acid phenol twice and with 24:1 chloroform-isoamyl 
alcohol twice, and then precipitated with 500 µL of isopropanol. Crude RNAs are purified by 
15% denaturing PAGE gel. 
Ligation of aa-pdCpA to tRNAC-3’ and Flexizyme charging: For a 200 µL reaction, mix 
the components on ice by the following order: 8 µL of 5 mM aa-pdCpA, 20 µL DMSO, 102 µL 
of water, 20 µL of 10x T4 ligation buffer (contains 500 mM Hepes-KOH pH 7.5, 150 mM 
MgCl2 and 7.5 mM ATP), 20 µL of 400 µM tRNA C-3’ and 30 µL of 10 kU/mL T4 RNA Ligase 
(New England Biolab Inc.). After incubate on 37 °C for 45 min, 30µL of 2M NaOAc pH 4.5 is 
added to quench reaction and N-protected aa-tRNA is recovered by EtOH precipitation and 
quantified by Qubit 2.0 Fluorometer.  Right before use, chemical acylated aa-tRNAs are 
illuminated with 100W, 350 nm UV (B100-AP from UVP LLC.) for 10 min on ice to remove 
NPPOC protecting group. Flexizyme charging is done exactly as described in (Murakami et al., 
2006) 
Protein purification and construction of PURE translation reaction 
 ԓ
42 
 
PURE translation plasmids are kindly provided by T. Ueda. Overexpression and 
purification of aaRS and translation factors follows procedure from (Shimizu and Ueda, 2010) 
exactly.  Ribosome is purified from strain RB1 (Wang et al., 2012) following same procedure as 
(Shimizu and Ueda, 2010). PURE translation master mix cocktail with limited aaRS and amino 
acids are prepared as follow. Solution A (5x) contains: 10 mM ATP, 10 mM GTP, 5mM CTP, 5 
mM UTP, 100 mM phosphocreatine, 250 mM Hepes-KOH pH 7.60, 500 mM KOAc, 65 mM 
Mg(OAc)2, 10 mM Spermidine, 5 mM DTT, 50 µg/mL formyl donor (Shimizu and Ueda, 2010). 
Solution B (10x) without EF-Tu contains: 12.12 µM IF1, 4.11 µM IF2, 4.86 µM IF3, 16.43µM 
EF-Ts, 6.44 µM EF-G, 1.21 µM AspRS, 0.86 µM GlyRS, 1.09µM LysRS, 0.28 µM MetRS, 0.29 
µM TrpRS, 0.13 µM TyrRS, 5.85 µM fmt, 0.89 µM rabbit muscle creatine kinase, 1.15 µM yeast 
myokinase, 0.64 µM nucleotide diphosphate kinase, 1.01 µM T7 RNA polymerase, 0.46 µM 
inorganic pyrophosphatase. Translation reaction is mixed as follow: prepare solutions on ice 
containing 1x Solution A, 1.36 mg/mL deacylated total tRNA (MRE600 total tRNA from Roche, 
incubate in pH 8.0, 250 mM NaBO4 buffer for 1 hr at 37 °C and then cleaned up by Zeba-
desalting column), 0.1 mM of each amino acid (Met, Asp, Gly, Tyr, Trp, Leu and Lys), 1x 
Solution B, 1.2 µM ribosome, 25 µM EF-Tu, 4 ng/µL DNA template. Incubate mixture at 37 °C 
for 1 hr right after addition of 24 µM photo-deprotected aa-tRNA.  The actual EF-Tu and aa-
tRNA concentrations used are described in each figure, otherwise 25 µM of EF-Tu and 24 µM of 
aa-tRNA are used.   
Western blot analysis of expressed peptides  
DNA Templates for the read-through assay are custom synthesized (Integrated DNA 
Technology) with sequence below (bold: translation initiation site; lower case: FLAG tag; 
underscore: unassigned codon, ex TAG, AAC, ACC or UCC): 
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5’GGCGTAATACGACTCACTATAGGGTTAACTTTAACAAGGAGAAAAACATGgattacaa
ggatgacgacgataagNNNCTGTGGATGAAGAAAATGAAAAAGGACTGGAAGTATCTCGATT
GGGACATGGACATGATGGACTATTGGTGGATGGATGACCTGTGGCTGGATTACAAA
TGGGATGATCTTATGCTGATGGATAAGTACCTGGATGATATGGATGATGATTACTTG
ATGGATATGATGGACGATTGGGATCTCATGTTATGGTACCTCTACATGTATCTCCTG
GATGACTGGGATATGTATAAGTAA3’ 
Translation reactions are quenched with equal volume of 2x tricine SDS sample buffer 
(Life technology) and analyzed on 16 % Tricine protein gel. Proteins are transferred to PVDF 
membranes by iBlot® (Life technology, setting program = P3, duration = 3 min 40 sec), and then 
blotted by anti-FLAG M2 antibody (Sigma F1804) and detected by SuperSignal West Femto kit 
(Pierce) and imaged by Bio-rad ChemiDoc™ MP system. 
Mutagenesis of EF-Tu  
Cloning was based on the EF-Tu overexpressing plasmid constructed by T. Ueda’s group. 
To describe their construct in brief, tufB gene was added EcoRI and BglII site (stop codon 
removed, therefore His6-tag coded on plasmid will be expressed) at N- and C-term and cloned 
into corresponding site of pQE60.  Top and bottom strand primers which carry mutations and 
have 12bp 5’-overlap on designated mutated location are used to amplify the whole wild-type 
EF-Tu plasmid. The linearized products are then reassembly to plasmid by GeneArt® Seamless 
cloning kit (Life technology). Primers used in this study are list below: 
Mutation Top strand primer Bottom strand primer 
D216A AAGCCGTTCCTGCTGCCGATCGAAGCGGTATTCTCCATC CAGGAACGGCTTGTCAATCGCACGCTCTGGTTCC 
V226A GGTCGTGGTACCGCGGTTACCGGTCGTGTAGAA GGTACCACGACCGGAGATGGAGAATACGTCTT 
V227A GGTCGTGGTACCGTTGCGACCGGTCGTGTAGAA GGTACCACGACCGGAGATGGAGAATACGTCTT 
T228A GGTCGTGGTACCGTTGTTGCGGGTCGTGTAGAA GGTACCACGACCGGAGATGGAGAATACGTCTT 
V258A ACCTGTACTGGCGCGGAAATGTTCCGC GCCAGTACAGGTAGACTTCTGAGTCTCTTTGATACCA 
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N273A CGTGCTGGTGAGGCGGTAGGTGTTCTGCTGCGTGGTATC CTCACCAGCACGGCCTTCGTCCAGCAGTTTGC 
V276A CGTGCTGGTGAGAACGTAGGTGCGCTGCTGCGTGGTATC CTCACCAGCACGGCCTTCGTCCAGCAGTTTGC 
L277A CGTGCTGGTGAGAACGTAGGTGTTGCGCTGCGTGGTATC CTCACCAGCACGGCCTTCGTCCAGCAGTTTGC 
Table 5. List of primers used in the mutagenesis EF-Tu.   
Amino acid analysis of expressed peptides  
Translation reactions are added 1/5 volume of dissociation mixture (contains 41.6 mM 
EDTA, 0.42 % Triton X-100 and 4.16M NaCl) and incubate on ice for 10 min. Peptide products 
from every 100 µL translation reaction mixture are bound to three successive batches of 10 µL 
anti-FLAG M2 magnetic beads (Sigma M8823) and washed with HST buffer (contains 5 mM 
Hepes-KOH pH 7.37, 150 mM NaCl, 0.05 % Tween-20) three times. After washed once more 
with HS buffer (HST buffer without Tween-20), the peptide products are eluted with 100µM 
FLAG peptide dissolved in HS buffer and then purified by HPLC (Equipment: Agilent 1260 
series pump with fluorescence detector, column: Eclipse Plus C18 1.8 µm, 2.1 × 150 mm; buffer 
A: 0.1% TFA in water; buffer B: 0.1% TFA in acetonitrile; flow rate: 0.4 mL/min; gradient: 5% 
to 65% buffer B from 0 to 20min; FLD: excitation 277 nm, emission 355 nm). Fractions 
corresponding to peptide products are pooled and concentrated to dryness by speedvac and 
hydrolysis by 6N HCl vapor at 110°C under argon. Hydrolysates are resuspended in 25 µL 
buffers (containing 25% v/v acetonitrile and 0.2 M NaBO4 buffer pH 7.8), and derivatized by 
mixing 25 µL of 0.9 mM (+)-1-(9-Fluorenyl)ethylchloroformate (FLEC). After incubating for 30 
min at room temperature, the derivatizing reaction is quenched by the adding 5 µL of 1M KBO4 
pH 10.4 and the excess (+)-FLEC related impurities are removed by washing the mixture with 15 
µL hexane 4 times. The aqueous phase is acidify by 5 µL 2M H3PO4 and analyzed by HPLC 
(column: Eclipse Plus C18 1.8 µm, 3.0 × 100 mm; buffer A: 8% acetonitrile, 12% 
tetrahydrofuran, 80% 30 mM NaOAc pH 4.38; buffer B: 40% tetrahydrofuran, 60% 30 mM 
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NaOAc pH 4.38; flow rate: 0.5 mL/min; gradient: 10% buffer B from 0 to 5 min, 10% to 30% 
buffer B from 5 to 13 min, from 30% to 100% solution B from 13 to 30min and at 100% solution 
B till 40min; FLD: excitation 263 nm, emission 313 nm) 
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Summary 
In this chapter, we describe a novel method to derivatize ribosome 23S rRNA into a 
library containing defined rate of insertion, deletion and randomization mutations. We also 
designed and implement a 12-round selection scheme with gradual elevating selection pressure 
on both the bulkiness of amino acid D-side chain and the incorporation frequency of these amino 
acids on synthesized peptide. We found that the selection led to pool of mutants with activities 
diminished comparing to wild type but even comparing to each other on the synthesis of DPhe 
containing peptide. Future engineering to restore the entropic effect of peptidyl transfer catalysis 
would be needed to generate ribosome capable to efficiently incorporate D-amino acid. 
Introduction 
Previously we demonstrated two new approaches, i.e. optimizing aa-tRNA:EF-Tu 
interaction and relaxing EF-Tu aa-binding pocket, to improve the incorporation of D-aa into 
protein translation. In this chapter we describe the third attempt: engineering ribosome. Dedkova 
et al. has pioneered in this field by showing that mutations in core peptidyl transfer center (PTC, 
2447-2450 and 2457-2462) could result in increased amber codon suppression corresponding to 
D-aa-tRNA (Dedkova et al., 2003). As a follow-up, we aim to build a platform to discover 
potential novel mutants with higher D-aa incorporation capacity in a high-throughput fashion. In 
protein engineering, two principles are often exercised, one is to translate the selection pressure 
into viability or binding affinity in order to enrich the desired mutants in batch from a population, 
and the second is to connect phenotype to genotype, so that active mutants could be identified 
conveniently by sequencing their genotypes. Since, the peptidyl transfer center of ribosome is all 
composed by 23S rRNA (domain V), a library of mutagenized rRNA sequences play both 
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phenotypes and genotypes, and hence the 2nd criterion is fulfilled by default. In order to turn D-
aa incorporation activity into a binding assay, we constructed a ribosome display platform based 
on two facts: a) ribosomes stall as stable complex with mRNA and nascent peptide when it 
cannot incorporate more amino acids or terminate properly; b) the nascent peptide needs to grow 
to ca. 40 residues to have the first residue been accessible (Forster et al., 2004). The scheme in 
Figure 11 illustrates our platform. The N-terminus FLAG-tag serves as handle to pull down 
active mutants, but it would only be exposed when ribosome read-throughs a few codons 
reassigned to D-aas (or Uaa in general). The enriched mutant pool could then be recycled to the 
next round of selection and sequenced.    
           
Figure 11. Selection platform for ribosome mutants based on ribosome display. The N-terminus 
FLAG-tag serves as handle to pull down active mutants, which will only expose when ribosome 
read-through a few codon reassigned to U-aas, including Daa and α, α-dialkylamino acid. 
Results 
Design and construction of library 
While choosing regions of rRNA sequence to mutate, we notice that almost all positions 
proximal or proven critical to peptide transfer center (Fernández-Suárez et al., 2014) of 23S are 
highly conserved (Cannone et al., 2002), which implies traditional saturated mutagenesis strategy 
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would easily results in double or triple whammy in activity. From the recent crystal structure 
(Voorhees et al., 2009), we also notice that in several regions around peptide transfer center, 
rRNA is packed as loop or coil instead of complementary stem, so changing the crowdedness 
might impact as well as swapping specific inter-base hydrogen bonding.  Therefore, utilizing 
recent technology advance in massive parallel oligo synthesis, we wrote script to render all 
mutated sequences with assigned mutation rate of each type, such as insertion, deletion, and base 
change, had one million species of them be synthesized on one microchip, and assembled to full-
length 23S rRNA gene. The rRNA residues within 20 Å distance to PTC are picked and 
subjected to mutating scripts no matter what their local secondary structures are. The list of 
regions containing mutations is shown in Table 6 below. Mutation rates are set as: deletion 
0.05%, insertion 0.03%, and randomization 0.015% for all regions. 
Region Num. of residues Region 
Num. of 
residues Region 
Num. of 
residues 
U566-G577 12 A1668-A1679 12 G2271-C2275 5 
G674-C678 5 U1779-A1786 8 G2436-A2461 26 
G742-U755 14 A1937-A1966 30 G2490-U2511 22 
G777-A793 17 G1983-C1985 3 C2551-C2558 8 
U827-G830 4 G2027-G2035 9 G2569-C2611 43 
G956-U963 8 A2052-C2073 22 
C1251-U1255 5 A2247-G2256 10 Total 263 
Table 6. List of regions and numbers of residues selected for mutation. 
With pools of synthetic oligos containing numerous mutations, next we consider the 
construction of ribosome library. The mutagenesis of prokaryote ribosome in vivo has been 
greatly limited by its indispensable role in massive and accurate protein production for cell 
survival; however, our attempts to assemble ribosome in vitro from in vitro prepared rRNA and 
ribosomal protein parts also suffer from very low efficiency possibly due to multiple rRNA base 
modifications. Given that our goal to mutate the core 23S rRNA will inevitably compromise 
ribosome activity in standard peptide bond synthesis, if we prepare ribosome library in vitro 
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would likely lead to a double whammy. We therefore use a transient expression method 
(Youngman and Green, 2005) to express the ribosome library in vivo, and inducing mutants with 
a titratable tetO-promoter to  ca. 10% of total ribosome population, and followed by isolation 
mutants from constituent ribosome through the MS2-tag inserted on loops of 23S rRNA (Figure 
12). 
 
Figure 12. Illustration of our library preparation procedure. Chip oligos are joined by overlape-
extention PCR into one 2 kb piece, and cloned into plasmid with the rest of rRNA genes from 
rrnB operon under tetO promoter. Library of plasmids are transformed in batch, and purified in 
two steps to yield mutant 70S ribosome. 
Selections with stepwise increasing stringency 
Our in vitro ribosome selection is based on the amber-codon suppression by unnatural 
amino acid in the expression of peptides beginning with a FLAG-tag, as summarized in Figure 
11. The amber codons are placed in locations closely after FLAG-tag coding region so that 
mutants capable to incorporate unnatural substrate will read though and hence able to display 
FLAG epitope from the nascent peptide channel. At once, we attempted to use D-Lysine(Biotin) 
as handle instead of FLAG-tag, so if mutants can incorporate it into peptide, the ribosome-
peptide-mRNA complex can be pull down.  The method was later replaced by FLAG-tag 
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because of its low efficiency and inflexibility. But in that experiment, we found that we always 
get wild type sequence dominated in all tested condition. To explain, since in this experiment, at 
least 40 subsequent L-aa-to-L-aa peptide pond formations are required to have the handle 
exposed from ribosome exit tunnel; this gave ribosomes 40:1 selection pressures on L- versus D-
peptide bond formation. While adding more amber codons in the template could help to balance 
L versus D-peptide bond amount, the low efficiency of D-amino acid incorporation might cause 
trouble. Therefore, we designed and carried through a selection consists of 12 rounds, in which 
the ribosome libraries translated templates round by round with increasing frequency of single 
amber codon, i.e. from 1 over every 12 codons to 1 over every 3 codons, increasing frequency of 
successive amber codon, and with increasing chirality of amino acids, i.e. from 2, 2-dimethyl to 
D-2-ethyl-2-methyl-amino acid, D-Ala, D-Val, and finally to D-Phe4. This is illustrated in Figure 
13 below. 
 
                                                     
4 We thought D-Phe is one of the difficult-to-incorporate D-aa when we performed this experiment. Later report 
from Fujino et al. shows D-Phe was actually relatively easy-to-incorporate among all 19 D-aas (Fujino et al., 2013). 
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Figure 13. Selection scheme. On the left is the five different templates used, the label indicates the 
frequency of amber codon and the number of consecutive amber codons. One the right is the table 
of amino acids and templates used in the 12 rounds of ribosome displays. 
After every two cycles, rRNA of the pool of selected mutants is extracted and analyzed. 
Sequence analysis and functional assay 
We analyzed the 23S rRNA of mutants pull-down by anti-FLAG antibody by Sanger 
sequencing, and the interesting mutants are cloned individually for further characterization. We 
once attempted to adapt two next-generation sequencing methods, 454 pyrosequencing and 
PacBio’s SMRT sequencing into our analysis but unfortunately both of their error rates (10% in 
454, and 3% in PacBio) are too high to cope with.  After we carried out 12 rounds of selection 
and enrichment procedure, around 90 sequences acquired from every two rounds are aligned by 
clustalW2 algorithm and represented as phylogenetic trees (Letunic and Bork, 2011) (Figure 14). 
The first observation among these trees is that a significant and distant clade emerged on round 6 
and reappears in all later rounds. When merging sequences from round 6 to 12 into a new tree, 
these distant clades can all traced back to the same ancestor. Along the selection cycles, if 
disregarding those outlier clades, the overall distances among species reduced, with the 
extremely distant species removed. Further examination of the outlier clades indicates that they 
contains much more mutations on regions not covered by chip oligos, and the Blast of their 
sequences against NCBI nucleotide database shows that they are 99% identical to Pseudomonas 
aeruginosa 23S rRNA.  
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Figure 14. Phylogenetic analysis of sequence data collected from every two rounds of selection. 
Outlier clades appear since round 6 are colored. Tree plot without outlier clades for round 8, 10, 
12 are showed in box.  Outlier mutants picked are shown in trees from merged pool of round 6, 8, 
10 and 12. Sequence of G3 are found to be 99% identical to Pseudomonas aeruginosa 23S rRNA, 
while G1, 2, 4 and 5 are various “DNA shuffling” hybrids between P. aeruginosa and E. coli 23S 
rRNA sequence. Mutant NP1 to NP5 are randomly picked from tree of round 12 without P. 
aeruginosa clade.  
We arbitrarily pick five sequences from the merged tree (named as G1 to G5, taken from 
clades with color background, Figure 14), and another five spequences (NP1 to NP5, as for non- 
Pseudomonas) from the round 12 tree with contaminating P. aeruginosa removed. Their aligned 
sequences and list of mutations are presented in Appendix C. In brief, mutants G1 to G5 which 
have various degree of DNA sequence shuffling from P. aeruginosa contain 108-275 mutations 
with the majority on the surface of 50S ribosome subunit. On the other hand, mutants NP1 to 
NP5 contains only 8-24 mutations, but still, the majority of them are not result from originally 
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designed oligos. We prepared the corresponding mutant ribosomes and test their capacity on 
translation and D-aa incorporation. 
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Figure 15. Assay for translation activity and DPhe incorporation of several random picked mutants. 
P. aeruginosa related mutants G1-G5 show various translation activity on normal peptides, and 
low but even activities on peptides containing DPhe. Non-P. aeruginosa related mutants also have 
various translation activities, with NP2 shows slightly higher yield ratio toward DPhe containing 
peptide. mRNA with label “---” is a template without middle NNN codon and hence full-length 
peptide synthesis doesn’t require chemically acylated tRNA. 
As shown in Figure 15, to our surprise, the P. aeruginosa and E. coli hybrid ribosome 
mutants G1 to G5 shows various level of translation activity on peptide containing normal amino 
acids, and also shows lower but even overall efficiency when synthesizing peptide containing  
DPhe. Densitometric analysis is done by first measure the intensity ratio of bands corresponding 
to normal peptide and DPhe-containing peptide for every ribosome mutants, and then these ratios 
are normalized to wild-type ribosome (as 1.0). For non-Pseudomonas related mutants, only NP2 
shows slightly higher yield ratio toward DPhe containing peptide comparing to wild-type, none of 
the other mutants performs better than wild-type.  We are testing these mutants with more D-
amino acids now to see if any of them are capable to translate more efficiently than wild-type 
ribosome.  
Discussion 
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In this chapter, we aimed to explore the possibility of expanding ribosome’s substrate 
tolerance, by generating a mutant library of 23S rRNA. On the selection platform, we used 
various amino acids including α,α-dialkylamino acids to gradually increase selection pressure. 
The additional advantage of using α,α-dialkylamino acid is that, since ribosome is more tolerable 
to them than to D-aa, this would enable us to use templates encoding more U-aa, i.e. more 
balanced templates in terms of the ratio of encoded U-aa versus L-aa.   
We identified several interesting 23S rRNA mutants after the selection. First, the 
appearance of Pseudomonas-derived mutant is unexpected, and remains elusive, but it is 
surprising that swapping ca. 2000 bp out of 2953 bp 23S rRNA sequence to Pseudomonas 
aeruginosa in mutant G3 still left us ribosome with measurable activities. It has been shown that 
ribosome from Pseudomonas sp. can utilize E. coli translation factors and aa-tRNAs in cell 
extract based system (Landau et al., 1977), but swapping rRNA is unprecedented. Regarding 
mutants NP1 to NP5, it is also unclear to us how those non-designated mutations are generated; 
presumably they are errors from PCR amplification. For both types of mutants, although various 
activities are observed for expression regular peptide, they all show lower than wild-type 
activities in making DPhe-containing peptide, suggesting that mutations diminish ribosome’s 
catalytic power.  
Considering the substrate-assisted catalysis hypothesis and the ab initio modeling of the 
transition state of peptidyl transfer (Wallin and Åqvist, 2010; Weinger et al., 2004), catalysis of 
peptidyl transfer reaction is conferred mainly by entropic effect, and to less extent by proximal 
effect. Specifically, ribosome promotes peptide bond formation mainly by organizing water 
molecules, peptidyl-tRNA and aa-tRNA into proper conformations.  Therefore, perturbation on 
this reaction either by designated mutations around PTC or by the use of D-aa-tRNA would 
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cause the loss of pre-organized conformation and hence the vast majority of catalytic power. 
That is to say, replacing L-aa by D-aa not only creates steric clash in PTC pocket but the 
misaligned hydrogen bonding which greatly deteriorates the entropic effect. This could explain 
why some mutants, such as G3 and G5, express normal peptide as worse as peptide containing 
D-aa, as they probably already lose entropic catalysis effect.   
Therefore, to re-build entropic effect-based catalysis might be one important direction to 
consider. Current wild-type ribosome architecture is well-suited for L-aa peptidyl transfer but 
stereo specificity is contributed to a great extent by L-aa-tRNAs themselves. To build a ribosome 
that catalyzes both D-aa and L-aa efficiently would likely involve a different mechanism, or 
potentially require help from other protein factors, such as the help of elongation factor P on 
translation of consecutive proline residues (Doerfel et al., 2013; Ude et al., 2013). 
Materials and Methods 
Construction of rRNA plasmid library 
Plasmid p278MS2 contains entire rrnB operon under promoter PL and with 23S rRNA 
tagged by MS2 hairpin is kindly provided by R. Green (Youngman and Green, 2005). A new 
plasmid ptet278 is constructed by first digesting p278MS2 with MfeI and KpnI, and swapping its 
promoter to tetO by reassembly with dsDNA oligos: 5’-AATTCAATTG TCCCTATCAG 
TGATAGAGTT GACATCCCTA TCAGTGATAG AGATAATGGG TACCGTAC-3’, using 
GeneArt® Seamless Cloning kit (Life Technology). The ptet278 plasmid is amplified with primer 
RID-11T and RID-11B (Table 8) to acquire the plasmid backbone except ca. 2 kb region of 23S 
gene to be mutated.  
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Mutagenesis oligos pools are synthesized by Custom Array® 12k format, with sequences 
generated by python script (Appendix A) based on sequences from eight 170 bp regions of 23S 
rRNA (Table 7). Mutation rate are set as below: insertion 3%; deletion 5%, randomization 1.5%. 
Oligo Sequence 
RID-1 
TAGGCGTGTGACTGCGTACCTTTTGTATAATGGGTCAGCGACTTATATTCTGTAGCAAGGTTAAC
CGAATAGGGGAGCCGAAGGGAAACCGAGTCTTAACTGGGCGTTAAGTTGCAGGGTATAGACCC
GAAACCCGGTGATCTAGCCATGGGCAGGTTGAAGGTTGGGTA 
RID-2 
ACACTAACTGGAGGACCGAACCGACTAATGTTGAAAAATTAGCGGATGACTTGTGGCTGGGGGT
GAAAGGCCAATCAAACCGGGAGATAGCTGGTTCTCCCCGAAAGCTATTTAGGTAGCGCCTCGTG
AATTCATCTCCGGGGGTAGAGCACTGTTTCGGCAAGGGGGTC 
RID-3 
ATCCCGACTTACCAACCCGATGCAAACTGCGAATACCGGAGAATGTTATCACGGGAGACACACG
GCGGGTGCTAACGTCCGTCGTGAAGAGGGAAACAACCCAGACCGCCAGCTAAGGTCCCAAAGT
CATGGTTAAGTGGGAAACGATGTGGGAAGGCCCAGACAGCCAG 
RID-5 
TGAGAGAACTCGGGTGAAGGAACTAGGCAAAATGGTGCCGTAACTTCGGGAGAAGGCACGCTG
ATATGTAGGTGAGGTCCCTCGCGGATGGAGCTGAAATCAGTCGAAGATACCAGCTGGCTGCAAC
TGTTTATTAAAAACACAGCACTGTGCAAACACGAAAGTGGACG 
RID-7 
GGTCCTAAGGTAGCGAAATTCCTTGTCGGGTAAGTTCCGACCTGCACGAATGGCGTAATGATGG
CCAGGCTGTCTCCACCCGAGACTCAGTGAAATTGAACTCGCTGTGAAGATGCAGTGTACCCGCG
GCAAGACGGAAAGACCCCGTGAACCTTTACTATAGCTTGACA 
RID-8 
AGGCTTTGAAGTGTGGACGCCAGTCTGCATGGAGCCGACCTTGAAATACCACCCTTTAATGTTTG
ATGTTCTAACGTTGACCCGTAATCCGGGTTGCGGACAGTGTCTGGTGGGTAGTTTGACTGGGGCG
GTCTCCTCCTAAAGAGTAACGGAGGAGCACGAAGGTTGGC 
RID-9 
CGCGAGCAGGTGCGAAAGCAGGTCATAGTGATCCGGTGGTTCTGAATGGAAGGGCCATCGCTCA
ACGGATAAAAGGTACTCCGGGGATAACAGGCTGATACCGCCCAAGAGTTCATATCGACGGCGGT
GTTTGGCACCTCGATGTCGGCTCATCACATCCTGGGGCTGAA 
RID-10 
GTAGGTCCCAAGGGTATGGCTGTTCGCCATTTAAAGTGGTACGCGAGCTGGGTTTAGAACGTCG
TGAGACAGTTCGGTCCCTATCTGCCGTGGGCGCTGGAGAACTGAGGGGGGCTGCTCCTAGTACG
AGAGGACCGGAGTGGACGCATCACTGGTGTTCGGGTTGTCAT 
Table 7. Sequences used to generate rRNA mutagenesis oligos. Underscore bases are regions to be 
mutated. Fragment RID-4 and RID-6 contains no residue to mutate. 
Primer Sequence 
RID-1T AGCACGCTTAGGCGTGTGACTGCGTACC 
RID-1B CTCCAGTTAGTGTTACCCAACCTTCAACCTGCC 
RID-2T TTGAAGGTTGGGTAACACTAACTGGAGGACCGAA 
RID-2B GTAAGTCGGGATGACCCCCTTGCCGAAACAGT 
RID-3T AAGGGGGTCATCCCGACTTACCAACCCGAT 
RID-3B CCAACATCCTGGCTGTCTGGGCCTTCCC 
RID-4T AGGCCCAGACAGCCAGGATGTTGGCTTA 
RID-4B CACCCGAGTTCTCTCAAGCGCCTTGGTATTC 
RID-5T GGCGCTTGAGAGAACTCGGGTGAAGG 
RID-5B ACACCGTATACGTCCACTTTCGTGTTTGCACAG 
RID-6B-2 TTAGGACCGTTATAGTTACGGCCGC 
RID-6B TTAGGACCGTTATAGTTACGGCCGCCGTTTACCGGGGCTTCGATCAAGAGCTTCGCTTGCGCTAA
CCCCATCAATTAACCTTCCGGCACCGGGCAGGCGTCACACCGTATACGTCCACTTTCGTG 
RID-7T CGGCCGTAACTATAACGGTCCTAAGGTAGCG 
RID-7B CCTACACATCAAGGCTCAATGTTCAGTGTCAAGCTATAGTAAA 
RID-8T CTGAACATTGAGCCTTGATGTGTAGGATAGGTGGGAGGCTTTGAAGTGTGGACGC 
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RID-8B TATGCCATTGCACTAACCTCCTGATGTCCGACCAGGATTAGCCAACCTTCGTGCTCCTCC 
RID-9T GACGGCGCGAGCAGGTGCGAAAG 
RID-9B TGGGACCTACTTCAGCCCCAGGATGTGATG 
RID-9T-2 GAGGTTAGTGCAATGGCATAAGCCAGCTTGACTGCGAGCGTGACGGCGCGAGCAGGTGCG 
RID-10T TGGGGCTGAAGTAGGTCCCAAGGGTATGG 
RID-10B CCATTGGCATGACAACCCGAACACCAGT 
RID-11T GTGTTCGGGTTGTCATGCCAATGGCACTGCCCGGTAGC 
RID-11B CGCAGTCACACGCCTAAGCGTGCTCCCACTGCTTGTACGT 
rRT1 AGGACCCTACTAGTAAAGATGGGTAATCCTCATCA 
Table 8. Primers used to amplify rRNA mutagenesis oligos and assemble them into one fragment. 
From RID-1 to 10, each fragment are amplified by corresponding primers with KAPA™ 
SYBR® FAST qPCR Kits till mid-log phase. Fragment RID-4 and RID-6 contains no mutation, 
so plasmid ptet278 is used as template. They are assembled by overlap-extension PCR and clone 
to linearlized ptet278 plasmid to yield plasmid library in DH5α-pro which has high level of tetR 
to suppress mutant rRNA expression.  
Purification of ribosome library or individual mutant 
Plasmid pMS2-MBP-His is kindly provided by R. Green’s group, and protein MS2-MBP 
is overexpressed and purified according to their procedure (Youngman and Green, 2005).  
Mutant library or individuals are grown in 1 L of 2YTPG media (1.6% Yeast Extract, 1% 
Tryptone, 0.5% NaCl, 5 g/L glucose, 22.05mM KH2PO4 and 39.26 mM K2HPO4) with 100 
µg/mL Carbenicillin in 2.5 L Tunair® flask and harvested at OD600 ~ 3.0. The wet cell paste was 
resuspend in buffer A (20 mM Hepes-KOH, pH 7.6, 100 mM NH4Cl, 10 mM Mg(OAc)2, and 0.5 
mM EDTA) and pass through a French Press, and cell debris was removed by centrifugation 
twice at 30,000g for 20 min. Supernatants are layered over 10 mL buffer B (20 mM Hepes-KOH, 
pH 7.6, 500 mM NH4Cl, 10 mM Mg(OAc)2, 0.5 mM EDTA and 37.7% Sucrose) and spin at 
45,000 rpm in rotor Type 70 Ti for 12 hr. Crude ribosome pellet is resuspended in buffer A 
without EDTA, loaded over 1 mL amylose column pre-bound with MS2-MBP protein and 
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washed with  10 mL buffer A without EDTA. Mutant ribosomes are eluted with buffer A without 
EDTA plus 10 mM Maltose, concentrated, and dialysis against storage buffer (20 mM Hepes-
KOH, 30mM HCl, 10 mM Mg(OAc)2 and 7 mM 2-βME). 
Selection of mutants by ribosome display  
Translations are done with customized PURExpress kit (New England Biolab Inc.), in 
which release factors, ribosome, amino acids and tRNAs are dropped out from other components. 
DNA templates sequences are listed in Appendix B. A typical 50 µL translation reaction contains: 
1x Solution A, 1x Factor mix, 0.1 mM each amino acids, 1.85 mg/mL total tRNA (Roche), 1µM 
ribosome library, 2 µM photo-deprotected aa-tRNA and 10 ng/µL DNA template. The mixture is 
incubated at 37 °C for 1 hr, shacked in anti-FLAG microtiter plate for 30 min, 750 rpm at 30 °C, 
and washed with WBT buffer (50 mM Tris-HOAc pH 7.4, 150 mM NaCl, 50 mM Mg(OAc)2, 
0.05% Tween-20) four times. Bound ternary complex is dissociate with 100 µL denature buffer 
(300 mM NaOAc pH 5.5, 0.25% SDS, 15 mM EDTA, 50 µg/mL Yeast tRNA) and denatured by 
vortexing with 100 µL acid phenol for 2 min. The aqueous phase is washed once more with 
phenol and twice with 24:1 chloroform-isoamyl alcohol followed by ethanol precipitation. 
Resuspended rRNA is reverse-transcribed by SuperScript® III reverse transcriptase (Life 
Technology) with primer rRT1 and amplified by primer RID-1T and RID-10B. This mixture of 
fragment is then clone back to linearized ptet278 backbone and transformed to DH5α-pro for 
next round of selection of sequencing analysis.   
Sequence analysis  
Sequence of each mutant is assembled from three Sanger sequencing reads. Sequences 
from every 2 rounds of selection are pooled and aligned by Muscle Command line algorithm. 
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The alignment files are loaded onto the ClustalW2-Phylogeny server on EMBL-EBI website to 
generate phylogenetic trees. Trees are edited by TreeGraph 2 (Stöver and Müller, 2010) and 
plotted by interactive Tree of Life webserver (Letunic and Bork, 2011).  
Western blot and translation activity assay  
Same procedure as described in chapter 2 is followed. 
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Chapter 4: Synthesis of 2’-deoxy-3’-mercapto-tRNA Substrate for 
Ribosomal Polyketide Synthesis  
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Summary 
We fused polyketide substrate, i.e. malonyl thioester to tRNA 3’-terminus, in order to 
examine if we could realize template-directed polypeptide or polyketide synthesis by the in vitro 
translation system. Synthesis of 2’-deoxy-3’-S-malonyl-tRNA substrate is achieved, but the 
preliminary attempts to incorporate it into ribosomal peptide synthesis is not successful. The 
labile thioester bond is suspected to cause this issue, and hence several strategies have been 
proposed to address it. 
Introduction 
Many strategies have been developed in an attempt to make artificial polyketides, due to 
their high potential clinical value, such as combinatorial synthesis or biosynthesis (McDaniel et 
al., 1999; Menzella et al., 2005). Split-pool solid-phase combinatorial synthesis (Goess et al., 
2006) was able to produce more than 10,000 new compounds, but since same chemistries are 
applied at each diversify step, most of the library compounds share similar skeletons. Genetic 
engineering of the polyketide synthesis (PKS) pathway, on the other hand, has a record of 
building over 50 variants of 6-deoxyerythronolide B (DEBS) (Xue et al., 1999). However, it is 
only in a few systems like DEBS that we know thorough information about the domain DNA 
sequences and their spatial orientations in the modules that lead to the consecutive processing, 
where we could then rationally engineer the pathway to have reasonable yields (Weissman and 
Leadlay, 2005).    
We aim to develop a new strategy for building more diversified polyketide skeletons by 
integrating ketide and peptide synthesis, two types of molecule that span distant structural and 
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functional space, into a single, programmable platform, i.e. ribosomal translation.  Protein 
translation and polyketide assembly-line synthesis share a similar polymer extension mechanism 
(Figure 11a, c) (Ferrer et al., 1999; Gindulyte et al., 2006), although one follows information 
from RNA templates and the other works based on modular enzyme architecture.  Intrigued by 
the diverse reactivity and broad substrate categories of PKS, we attempted to transplant the core 
of polyketide synthesis unit and fused it into the integrated ribosome translation machineries to 
collect the merits of both. Specifically, we would like to swap the peptidyl transfer reaction from 
amide formation to Claisen condensation which is the typical polyketide extension reaction. The 
chemical acylation methods described in previous chapters are adapted to prepare tRNA malonyl 
substrates that mimic polyketide synthesis. In this chapter we will describe how tRNA with 3’-
hydroxy or 3’-mercapto group is synthesized and acylated by malonyl ketide building block and 
our preliminary attempts on subjecting them into in vitro translation system. 
          
 
Figure 16. (a) mechanism of chalcone synthetase, redrawn from Ferrer et al. (Ferrer et al., 1999) (b) 
sketch representation of acyl transfer of peptide synthesis and its ketide synthesis mimic, drawn 
based on structure solved by Voorhees R. et al (Voorhees et al., 2009) (c) contexts of (b), magenta 
sticks: P-site tRNA (Phe); wheat sticks: A-site tRNA (Phe); blue cartoon: T. thermophilus 23S 
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rRNA; pale green cartoon: L27 protein (d) structures of designed ketide building block carrier 
tRNA (PDB ID: 2WDK, 2WDL). 
Results 
Design and Synthesis of 2’-deoxy-3’-mercapto-tRNA 
Polyketide synthetases use a thioester to carry out polymerization due to its good 
reactivity toward unstable or weak nucleophiles such as enolates or the hydroxyl group.  Based 
on the mechanism of ketosynthetase described by Ferrer et al.(Ferrer et al., 1999) (Figure 11a), a 
histidine and an asparagine are required as hydrogen bond donors to stabilize the enolate 
intermediate formed after decarboxylation of the malonate half thioester. Direct substitution of 
the P- and A-site amino acid with thioester and enolate in recent ribosome X-ray crystal structure 
solved by Ramakrishnan’s group (Voorhees et al., 2009) is shown in Figure 11b (and Figure 11c 
for their interaction with surrounding residues). It is found that the closest ribosomal protein, L27, 
is 6.8Å away from the peptide transfer center, and the nearest hydrogen bond donor available for 
an A-site enolate is the P-site 2’-OH. Based on this analysis, tRNAs with two types of terminal 
“carrier module” are designed (Figure 11d), however, the carrier 2’-OH is not further pursued 
since 2’-OH will result in migration of the acyl group (Porcher et al., 2005). 
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Figure 17. Synthesis scheme for the preparation of 2’-deoxy-3’-mercapto-tRNA. 
PKS carrier tRNAs will be prepared by the 3’-terminus dinucleotide-ligation method first 
developed by Noren et al.(Ellman et al., 1991; Noren et al., 1989) The synthetic scheme of 3’-SH 
dinucleotides is shown in Figure 17. In brief, 3’-OH of commercial available 5’-DMT-adenosine 
(1) is first inverted by a Mitsunobu reaction, then mesylated and transformed to benzoyl-
protected thiol (3) by SN2 substitution. The 5’-DMT protection is removed and deoxycytidine as 
well as the terminal phosphate group are installed (5) via a standard oligonucleotide 
phosphoramidite method. After global deprotection with ammonium hydroxide, the resulting 
dinucleotides are loaded with malonate by aqueous transthioesterification (7). However, the 
attempt to ligate pdCpdA-S-malonyl with in vitro transcribed tRNAs was not successful (Figure 
18). In order to understand why the ligation fails, we prepared the disulfide dimer (8) of thiol (6) 
and also a p-hydroxyphenacyl (pHP) protected version of dinucleotide thiol (9), and compare 
their effect on T4 RNA ligase activity.  
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Figure 18. (a) Synthesis of disulfide dimer of dinucleotide pdCpdA-SH (6) and p-
hydroxyphenacyl protected dinucleotide (9); (b) 8% Acid Urea-PAGE analysis of dinucleotide 
ligation. pdCpdA-SH (6) is neither substrate nor inhibitor to T4 ligase; disulfide (8) and malonyl-
S-pdCpdA (7) act as enzyme inhibitor, their presence block the ligation of normal substrate Aib-
pdCpA (10); pHP-masked thiol (9) is a good substrate. (c) Synthesis of 2’-deoxy-3’-mercapto-
tRNA (13) from (9).     
On Figure 18c, when pdCpdA-S-malonyl substrate (7) is used, no ligation product, i.e. 
full length tRNA is detected, neither does pdCpdA-SH (6) substrate. However, an interesting 
effect is that, when mixing a standard dinucleotide substrate (10) into each ligation reaction, 
pdCpdA-S-malonyl (7) inhibits normal ligation of (10) to tRNA while pdCpA-SH (6) not. On the 
other hand, the disulfide dimer (8) also shows inhibitory effect on control ligation as pdCpdA-S-
malonyl (7). These suggest that T4 RNA ligase is sensitive to sulfhydryl modification reagents, 
either by oxidation or acylation, which is confirmed in literature (Eun, 1996). Although this 
couldn’t explain why free thiol (6) is not recognized as substrate, it suggests that masking the 
thiol with inert group might work. Indeed, pHP-protected dinucleotide is ligated to tRNA reaches 
ca. 50 % yield. The protecting pHP group is removed by photolysis and the tRNA-3’-thiol is 
acylated by malonyl-half-thioester (MAHT) to build the 2’-deoxy-3’-mercapto-tRNA.  
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However, LC-MS data indicates malonyl-thioester of pdCpdA-SH (7) is very unstable, 
only 80% of (7) hydrolyzed to (6) within 5 min incubation in pH 7 buffer at room temperature. 
And no thioester (7) is detected 30s after mixing it with 5 mM 1, 4-dithioerythritol.  When 
subject malonyl-S-tRNA (13) into the in vitro translation read-through assay as described in 
previous chapters, no signal is detected. We conclude that the following up experiment is to 
figure out a substitution for thiol reducing agents in PURE translation reaction, either 
biochemically by other reducing agents such as ascorbic acid, or physically degassing.   
Discussion 
A tool to incorporate polyketide units into protein synthesis and to integrate PKS 
decoration enzymes into the system will open tremendous new possibilities, not only that 
polyketides could be hybridized with peptides to make novel breeds of compounds but also that 
proteins could be dressed with ketides or vice versa for extended functional space.  All of these 
could simply be achieved by programming the DNA templates. The accumulated studies on 
protein properties today would add great leverage to our ribosomal polyketides strategy in that 
one can add any “Functional Group” module to ketides to expand their functional span. 
In this chapter, we described our attempt to integrate polyketide synthesis unit into 
ribosome translation system. A carrier tRNA with 3’-OH substituted by 3’-SH has been 
synthesized, and charged with standard polyketide substrate. However, since the thioester bond 
of tRNA-S-malonyl is labile in the presence of free thiol, further debugging is required. There 
are three intertwined issues to consider, one is to maintain reducing environment, since that 
scavenging DTT by adding Iodoacetamide seizes protein synthesis; another is the fast 
deacylation of thioester tRNA substrate needed to be addressed; and that high dosage of reactive 
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thioester such as tRNA-S-malonyl could potentially deactivate critical sulfhydryl group enzymes 
activity, ex. TrpRS. For the first issue, one idea would be to degas all PURE translation reaction 
thoroughly, but this would require meticulous operation. The other would be to find a non-thiol-
based reducing agent that could protect enzyme activities while keeping dissolved oxygen level 
low, such as ascorbic acid. For the second and third issue, flexizyme might be a potential means 
to re-charge tRNA. The use of catalyst to recycle tRNA-SH not only reduces the initial 
concentration of tRNA-S-malonyl, but also allows to reload tRNA-SH with less reactive reagents 
such as p-chlorobenzyl mercaptan MAHT (instead of very reactive thiolphenol MAHT). 
Materials and Methods 
General  
Solvents and reagents are purchased from Sigma Aldrich Inc. or EMD Merck without 
further purification.  1H NMR spectra were measured from Variant Mercury 400 MHz, Inova 
500 MHz and Agilent DD2 600 MHz instrument. High Resolution Mass spectra (HRMS) were 
obtained from Agilent 6210 Time-of-Flight LC/MS. Preparative HPLC was carried out with an 
Agilent 1200 system equipped with diode array detector, fraction collector and Zorbax PrepHT 
C18 column (21.2 x 250 mm, 7 µm). Flash chromatography is done by CombiFlash® Rf 200 with 
either RediSep® Rf Gold normal phase silica or C18 column. Thin layer chromatography (TLC) 
is done with 5 × 2 cm glass plate coated by Silica Gel 60 with F254 fluorescence indicator. 
Synthesis of compounds in this study 
N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyxyloadenosine (2): To a 250 mL 
three-necked flask were added N6-Benzoyl-2'-deoxy-5'-O-DMT-adenosine (1) (5.0 g, 7.6 mmol, 
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1 eq.), p-nitrobenzoic acid (2.55 g, 15.2 mmol, 2 eq.), and triphenylphosphine (4.0 g, 15.2 mmol, 
2 eq.) under nitrogen. Anhydrous THF (50 mL) was added to dissolve the reagents while stirring. 
After all material dissolved, diethyl azodicarboxylate (40% w/v in toluene, 6.9 mL, 15.2 mmol, 2 
eq.) was added drop wise over five minutes. Reaction progress was followed by TLC in EtOAc. 
After stirred 2.5 hr, solvent was evaporated and the crude solid was purified by flash 
chromatography with EtOAc. Fractions corresponding Rf = 0.67 (EtOAc) are pooled and 
concentrated to yield p-nitrobenzoylated alcohol as a yellow solid (5.66 g, 7.01 mmol, 92.3%).   
p-nitrobenzoylated alcohol (0.915 g, 1.34 mmol, 1 eq.) was then suspended in MeOH 
(130 mL) and cooled to 0 C, then a 0.2 M solution of NaOMe in MeOH (4.54 mL, 0.907 mmol, 
0.8 eq.) was added drop wise over two minutes, which fully dissolves p-nitrobenzoylated alcohol. 
Reaction progress was monitored by TLC eluting with EtOAc. No starting material remained 
after 35 minutes, and the reaction was quenched by saturated NH4Cl to pH 7 dropwisely and 
solvent was evaporated in vacuuo at room temperature yielding a crude pale yellow solid. The 
crude was purified by flash chromatographed on silica gel (EtOAc to 4:6 EtOAc/MeOH) to yield 
alcohol (2) as a transparent film (0.61 g, 0.93 mmol, 81.2%). Rf = 0.29 (EtOAc). 1H NMR (400 
MHz, DMSO) δ = 8.79 (s, 1H), 8.45 (s, 1H), 8.00-6.77 (m, 18H), 6.45 (d, 1H), 5.45 (d, 1H), 4.38 
(m, 1H), 4.22 (m, 1H), 3.69 (m, 6H), 3.2 (d, 1H), 2.79 (m, 1H), 2.49 (d, 1H). HRMS calculated 
mass for C38H35N5O6: 657.2587; found [M+H]+: 658.2758. 
N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-3'-S-benzoyl-2',3'-dideoxyadenosine (3): 
Alcohol (2) (0.606 g, 0.921 mmol, 1 eq.) was dissolved in anhydrous pyridine (7.2 mL) under 
nitrogen and co-evaporate with 5 mL pyridine in vacuuo twice. The residue was then dissolved 
in anhydrous pyridine (8.5 mL) and cooled to 0 °C. To the solution was sequentially added 
dimethylaminopyridine (DMAP) (0.125 g, 1.01 mmol, 1.1 eq.) and mesyl chloride (78.4 µL, 
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1.013 mmol, 1.1 eq.) dropwisely over two minutes. The reaction was allowed to warm to room 
temperature and stirred overnight. The reaction mixture was pour into DCM and H2O mixture 
and shacked vigorously. The organic phase is washed twice more with 0.1N HCl and dried with 
sodium sulfate, and then concentrated to yield pale orange crude solid (0.55 g), which was used 
without further purification. Rf = 0.52 (EtOAc). 1H NMR (600 MHz, CDCl3) δ = 8.84 (m, 1H), 
8.40 (s, 1H), 8.30 (s, 1H), 8.10-7.57 (m, 5H), 7.48-6.88 (m, 13H), 6.65 (m, 1H), 5.54 (s, 1H), 
4.42 (m, 1H), 4.19 (m, 1H), 3.74 (m, 1H), 3.41 (m, 1H), 3.03 (m, 3H), 2.80 (s, 1H), 2.41 (s, 1H). 
HRMS calculated mass for C39H37N5O8S: 735.2363; found [M+H]+: 736.2503. 
In 250 mL three-neck flask, mesylated alcohol (2.53 g, 3.44 mmol) is co-evaporated with 
10 mL anhydrous pyridine twice. 30 mL anhydrous DMF is added and the solution is heated 
under argon, and once the temperature reaches 100 °C, sodium thiobenzoate (1.37 g, 8.60 mmol) 
is added every 30 min for four times. 30 min after the last addition of sodium thiobenzoate, the 
reaction is followed by TLC and then cooled down to ca. 60 °C. DMF is slowly evaporated in 
vacuuo. The residue is dissolved in 250mL DCM and washed with 200mL of brine three times, 
dried over Na2SO4 and concentrated. The crude residue is purified by flash chromatography (70 
g SiO2, DCM/MeOH/TEA 98.5:1.5:0.3 to 98:2:0.3) to yield a clear yellow film of (3) (2.0 g, 
2.57 mmol, 74.8%). Rf = 0.32 (CH2Cl2/MeOH 19:1). 1H NMR (500 MHz, CDCl3) δ = 9.05 (s, 
1H), 8.81 (s, 1H), 8.03-7.51 (m, 10H), 7.49-6.78 (m, 13H), 6.15 (m, 2H), 5.30 (s, 1H), 4.59 (m, 
1H), 4.31 (m, 1H), 3.48 (m, 2H), 3.25 (m, 1H), 3.09 (m, 1H), 2.72 (m, 1H). HRMS calculated 
mass for C45H39N5O6S: 777.2621; found [M+H]+: 778.2684. 
N4-Benzoyl-P(O)-(2-cyanoethyl)-5’-O-(4,4’-dimethoxytrityl)-2’-deoxycytidylyl-
(3’→5’)-N6-benzoyl-3'-S-benzoyl-2',3'-dideoxyadenosine (4): First is to remove 5’-DMT from 
(3). To a solution of N6-benzoyl-3’-S-benzoyl-2’,3’-dideoxy-3’-thioadenosine (3) (2.05 g, 2.64 
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mmol, 1 eq.) in 50mL of DCM at 0 °C was added 25mL of 3% trifluoroacetic acid in DCM. The 
reaction was stirred for 7 min on ice and followed by TLC (DCM/MeOH 95:5). The color turns 
bright red upon addition of TFA. When complete, ca. 4 mL of MeOH was added followed by 
triethylamine. The reddish color turns back to light brown. The mixture is then extracted with 
100mL DCM and 200mL brine, dried over MgSO4, and concentrated. The crude residue is then 
purified by flash chromatography (70 g SiO2, 98:2 DCM/MeOH) to yield 0.60 g of a light yellow 
solid (N6-benzoyl-3'-S-benzoyl-2',3'-dideoxyadenosine, 1.26 mmol, 47.9%). 1H NMR (500 MHz, 
CDCl3) δ = 8.98 (s, 1H), 8.84 (s, 1H), 8.31 (m, 2H), 8.04-7.95 (m, 6H), 7.65-7.45 (m, 12H), 
7.30-7.26 (m, 3H), 7.05 (m, 2H), 6.45-6.43 (m, 3H), 5.00-4.63 (m, 5H), 4.62-4.60 (m, 5H), 4.33 
(m, 3H), 4.13-4.08 (m, 8H), 3.97-3.92 (m, 7H), 3.39-3.33 (m, 5H), 2.63-2.58 (m, 6H), 2.17-2.07 
(m, 5H), 1.71-1.55 (m, 4H), 1.27-1.25 (m, 4H). HRMS calculated mass for C24H21N5O4S: 
475.1314; found [M+H]+: 476.1387. 
In a dry 100 mL round-bottomed flask equipped with a magnetic stir bar, deprotected N6-
benzoyl-3'-S-benzoyl-2',3'-dideoxyadenosine (343 mg, 0.72 mmol, 1 eq.) was co-evaporated 
twice with 5 mL anhydrous pyridine and then dissolved in 8 mL anhydrous acetonitrile.  0.45M 
tetrazole in acetonitrile (8.0 mL, 3.6 mmol, 5 eq) was added to the flask and cooled to 0°C.  N4-
Benzoyl-2'-deoxy-5'-O-DMT-cytidine 3'-CE phosphoramidite (660 mg, 0.79 mmol, 1.1 eq.) was 
dissolved in 8 mL of anhydrous acetonitrile added into mixture, and the reaction was stirred form 
30 min at r.t.  I2 (220 mg, 0.87 mmol, 2.4 eq.) was dissolved in tetrahydrofuran/H2O/pyridine 
(2:1:0.1) and added to the solution dropwisely. After stirring ca. 15 mins, the solution is poured into 
ca. 150 mL DCM and extracted with 100 mL NaHSO3, the dark color of iodine disappeared. Collect 
organic phase and re-extract the aqueous phase with another 100 mL of DCM. The combined organic 
phase is washed with 200 mL brine, dried with Na2SO4 and concentrated. The crude residue is purified by 
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flash chromatography (120g SiO2, DCM/MeOH/triethylamine 98:2:0.3) to give a yellow film. 1H NMR 
(500 MHz, DMSO) δ = 9.23-9.21 (m, 2H), 8.91 (s, 1H), 8.49-8.41 (m, 2H), 8.09-8.08 (m, 2H), 
8.00-7.91 (m, 4H), 7.69-7.51 (m, 10H), 7.49 (s, 1H), 7.41-7.14 (m, 13H), 6.90-6.89 (m, 2H), 
6.59-6.55 (m, 4H), 6.37 (s, 1H), 5.36 (s, 1H), 5.25 (s, 1H), 4.69-6.68 (m, 2H), 4.52-4.42 (m, 5H), 
4.31-4.14 (m, 7H), 3.83 (s, 1H), 3.54-3.49 (m, 4H), 3.36 (s, 1H), 2.86-2.68 (m, 9H), 2.41-2.39 (m, 
2H), 2.32 (s, 1H), 2.13-2.03 (m, 3H), 1.61- 1.55 (m, 2H), 1.48-1.31 (m, 3H), 1.20 (s, 1H), 0.95-
0.93 (m, 3H). HRMS calculated mass for C64H58N9O13PS: 1223.3612; found [M+Na]+: 
1246.3477. 
N4-Benzoyl-P(O)-(2-cyanoethyl)-2’-deoxycytidylyl-(3’→5’)-N6-benzoyl-3'-S-benzoyl-
2',3'-dideoxyadenosine 5’-[bis(2-cyanoethyl)-phosphate] (5): To the solution of dinucleotide 
(4) (960 mg, 0.784 mmol, 1 eq.) in 20 mL of anhydrous dichloromethane at 0° C was added 10 
mL of 3% TFA in DCM. The mixture was monitored by TLC (5:95 MeOH/DCM). After 30 min, 
the reaction was quenched with 5 mL of MeOH and poured into 75 mL DCM. The solution is 
washed with NaHCO3 twice and brine once. The organic phase was dried by MgSO4 and 
concentrated to give 860 mg crude residue. The crude product was purified by flash 
chromatography (60 g SiO2, DCM/MeOH (from 97:3 to 93:7) to give 5’-deblocked dinucleotide 
(490 mg, 0.53 mmol, 67.8%). 1H NMR (500 MHz, CDCl3) δ = 9.37 (s, 1H), 9.18 (s, 1H), 8.86-
8.78 (m, 2H), 8.53-7.92 (m, 10H), 7.64-7.52 (m, 3H), 7.08 (s, 1H), 6.58 (s, 1H), 6.26-6.17 (m, 
2H), 5.37 (s, 1H), 5.16-3.87 (m, 14H), 3.55-3.19 (m, 3H), 2.83-2.68 (m, 2H), 2.49 (s, 1H), 1.28-
1.12 (m, 2H). HRMS calculated mass for C43H40N9O11PS: 921.2306; found [M+H]+: 922.2704.  
In a dry 100 mL three-neck flask equipped with a magnetic stir bar, 5’-deblocked 
dinucleotide (490 mg, 0.53 mmol, 1 eq.) was co-evaporated twice with 5 mL anhydrous pyridine 
and then dissolved in 8 mL anhydrous acetonitrile.  0.45M tetrazole in acetonitrile (5.9 mL, 2.66 
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mmol, 5 eq.) was added to the flask and cooled to 0°C.  Bis(2-cyanoethyl) 
diisopropylphosphoramidite (405 µL, 1.60 mmol, 3 eq.) was dissolved in 8 mL of anhydrous 
acetonitrile added into mixture, and the reaction was stirred form 30 min at r.t.  I2 (446 mg, 1.76 
mmol, 3.3 eq.) was dissolved in tetrahydrofuran/H2O/pyridine (2:1:0.1) and added to the solution 
dropwisely. After stirring ca. 15 mins, the solution is poured into ca. 100 mL DCM and extracted with 
100 mL NaHSO3, the dark color of iodine disappeared. Collect organic phase and re-extract the aqueous 
phase with another 100 mL of DCM. The combined organic phase is washed with 200 mL brine, dried 
with Na2SO4 and concentrated to yield pale yellow foam (580 mg, 0.52 mmol, 98.5%). The product is 
used for next step without further purification. 1H NMR (500 MHz, CDCl3) δ = 9.34 (s, 1H), 8.89-
8.71 (m, 2H), 8.53-8.51 (m, 2H), 8.13-7.91 (m, 6H), 7.71-7.59 (m, 6H), 7.58-7.42 (m, 6H), 7.32-
7.14 (m, 4H), 6.61 (s, 1H), 6.28-6.26 (m, 2H), 5.51 (s, 1H), 5.36 (s, 1H), 5.19-5.16 (m, 2H), 
4.78-4.68 (m, 8H), 4.57-4.23 (m, 17H), 3.81 (s, 1H), 5.54-3.34 (m, 5H), 3.07 (s, 1H), 2.93-2.80 
(m, 7H), 2.32-1.91 (m, 8H), 1.68 (s, 1H), 1.43-1.22 (m,7H). HRMS calculated mass for 
C49H47N11O14P2S: 1107.2500; found [M+H]+: 1108.2644.  
2’-deoxycytidylyl-(3’→5’)-3'-mercapto-2',3'-dideoxyadenosine 5’- dihydrogen phos-
phate Tris (triethyl-ammonium) Salt (6): In a pressure flask, dinucleotide (5) (50 mg, 0.045 
mmol, 1 eq.) and p-MeO-toluenethiol (125 µL, 0.90 mmol, 20 eq. as scavenger) are dissolved in 
2.5 mL of 1:9 dioxane/methanol. Concentrated ammonium hydroxide (2.5 mL, 29% ca.) was 
added to the reaction mixture and it was sealed and incubated at 55°C for 16 hr. The mixture is 
washed twice with 5 mL DCM to remove hydrophobic substance, and the aqueous phase is 
concentrated in vacuuo to give 39 mg crude residue. The crude was purified by reverse phase 
HPLC twice (Agilent Eclipse XDB-C18 column, 9.4 × 250 mm, first run: 0 to 50% linear 
gradient of acetonitrile in 50mM ammonium acetate over 50 min at flow rate 2 mL/min; second 
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run: 0 to 50% linear gradient of acetonitrile in 50mM triethylammonium acetate over 50 min at 
flow rate 2 mL/min) to yield product (6) (21.5 mg, 0.023 mmol, 50.7%). The product contains ca. 
0.5 eq. of benzoic acid impurity, but this would not affect downstream reaction. 1H NMR (600 
MHz, D2O) δ = 8.30 (s, 1H), 8.08 (s, 1H), 7.60 (d, 1H), 6.30 (d, 1H), 5.96 (q, 1H), 5.95 (m, 1H) 
4.58-4.55 (m, 1H), 4.09-4.04 (m, 4H), 3.86-3.84 (m, 2H), 3.72 (q, 1H), 3.09 (q, 18H), 2.88-2.84 
(m, 1H), 2.57-2.53 (m, 1H), 2.17-2.14 (m, 1H), 1.64-1.62 (m, 1H), 1.21-1.15 (t, 27H). HRMS 
calculated mass for C19H26N8O11P2S: 636.0917; found [M−H]−: 635.0748. 
2’-deoxycytidylyl-(3’→5’)-3'-S-malonyl-2',3'-dideoxyadenosine 5’- dihydrogen phos-
phate (7): To dinucleotide (6) (5mg, 7.86 µmol) in eppendorf tube is added 200µL of pH 7.1 
sodium phosphate buffer (40mM). Malonyl-half-thioester (21 mg, 109 µmol, 13.9 eq) was 
dissolved in 50 µL acetonitrile and added to reaction. The mixture is titrated to pH 6 by 0.1N 
NaOH and vortex at r.t. overnight. The reaction progress is monitored by HPLC, and after 
completion, the mixture was quenched by 50 µL of 5% formic acid and purified by HPLC (0 to 
25% linear gradient of acetonitrile in 0.1 % formic acid over 40 min at flow rate 10 mL/min) to 
yield (3.3 mg, 4.57 µmol, 58.1%). 1H NMR (600 MHz, D2O) 8.48 (s, 1H), 8.38 (s, 1H), 8.22 (s, 
1H), 7.83 (m, 2H), 6.40 (s, 1H), 6.09 (s, 1H), 5.98(s, 1H), 4.72 (m, 2H), 4.37 (s, 1H), 4.19 (s, 
1H), 3.92 (m, 3H), 2.73 (m, 3H), 2.32 (s, 1H), 1.28(s, 1H). HRMS calculated for 
C22H28N8O14P2S: 722.0920; found [M+H]+: 723.0998. 
Bis[2’-deoxycytidylyl-(3’→5’)-3'-mercapto-2',3'-dideoxyadenosine 5’- dihydrogen 
phosphate)] disulfide (8):  Dinucleotide (5) (200 mg, 0.180 mmol, 1 eq.) was deprotected 
following previous procedure. To the solution of crude dinucleotide thiol in 2 mL of 
tetrahydrofuran/ H2O/pyridine (2:1:0.1) is added Iodine (91.2 mg, 0.180 mmol, 2 eq.) and stirred 
for 1 hr at r.t. The solution is washed with 2 mL DCM twice and cleaned up by HPLC (0 to 25% 
 ԓ
78 
 
linear gradient of acetonitrile in 0.1 % formic acid over 40 min at flow rate 10 mL/min). Yield:  
51.7 mg (0.040 mmol, 45.2% over two steps) 1H NMR (600 MHz, D2O) δ = 8.41 (s, 2H) 8.22 (s, 
2H) 7.90 (d, 2H), 6.37-6.35 (m, 2H) 6.07 (d, 2H), 5.91-5.89 (m, 2H), 4.67-4.62 (overlapped with 
reference signal, 2H expected), 4.27-4.25 (m, 2H), 4.16-4.10 (m, 4H), 4.06-4.03 (m, 2H), 3.91-
3.83 (m, 6H), 2.98-2.97 (m, 2H), 2.80-2.76 (m, 2H), 2.37-2.33 (m, 2H), 1.94-1.90 (m, 2H). 
HRMS calculated mass for C38H50N16O22P4S2: 1270.1677; found [M+H]+: 1271.1721. 
2’-deoxycytidylyl-(3’→5’)-3'-S-p-hydroxyphenacyl-2',3'-dideoxyadenosine 5’-dihy-
drogen phosphate (9): Dinucleotide (5) (200 mg, 0.180 mmol, 1 eq.) was deprotected following 
previous procedure. To the solution of crude dinucleotide thiol in 2 mL of CH3CN/phosphate 
buffer pH 7.1 (1:1) is added 4-hydrophenacyl bromide (31.0 mg, 0.144 mmol, 0.8 eq). The 
solution is stirred at r.t. overnight, and purified by HPLC (0 to 25% linear gradient of acetonitrile 
in 0.1 % formic acid over 40 min at flow rate 10 mL/min). Yield:  ca. 84.5 mg (0.110 mmol, 
60.9% over two steps) 1H NMR (600 MHz, D2O) δ = 8.27 (s, 1H), 8.23 (s, 1H), 8.05 (s, 1H), 
7.76-7.73 (m, 2H), 6.72-6.71 (), 6.20-6.18 (m, 1H), 5.94 (d, 1H), 5.81-5.79 (dd, 1H), 4.14-4.11 
(m, 2H), 4.09-4.06 (m, 2H), 4.01-3.99 (m, 1H), 3.96-3.94 (d, 1H), 3.85 (m, 2H), 3.52-3.48 (m, 
1H), 2.69-2.67 (m, 1H), 2.49-2.47 (m, 1H), 2.25-2.23 (m, 1H), 1.82-1.77 (m, 1H). HRMS 
calculated mass for C27H32N8O13P2S: 770.1285; found [M+H]+: 771.1344. 
Photolysis of pHP-protected thiol: 
In clear eppendorf tube, 50 µL dinucleotide-thiol-pHP (9), 20 µL NaBO4 buffer (0.5 M, 
pH 8.0), 10 µL 0.5M DTT, and 20 µL Milli-Q water were combined and illuminated under 350 
nm UV light (21000µW/cm2, 3 min) on ice 0°C. The product is then analyzed by LCMS to 
confirm dinucleotide thiol (6) is recovered. 
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Appendix A: Python codes 
Python code for generating random insertion and deletion oligo sequences 
#!/usr/bin/env python 
from Bio import SeqIO 
from Bio.Seq import Seq 
from Bio.SeqRecord import SeqRecord 
from Bio import SeqFeature 
from Bio.Seq import MutableSeq 
from Bio.Alphabet import generic_dna 
 
def RID(wt,ins, det, LibSize): 
    #ins = rate of insertion(&) 
    #det = rate of deletion(%) 
    #LibSize = Number of oligos generated 
    import random 
    inscnt = 0 
    delcnt = 0 
    mutcnt = 0 
    j = 0 
    while j < LibSize:  
        target = wt.tomutable() 
        ghost = wt.tomutable() 
        i = 0 
        k = 0 
        while i < len(target): 
            R = random.random() 
            if R < ins*det:                        # deletion + insertion = randomize 
                target[i:(i+1)] = random.choice('atgc') 
                ghost[k:k+1] = "N" 
                mutcnt = mutcnt + 1 
                k = k + 1 
                i = i + 1 
            elif ins*det <= R < ins + ins*det:      # insertion 
                target[i:(i+1)] = target[i] + random.choice('atgc') 
                ghost[k:k+1] = "&" 
                inscnt = inscnt + 1 
                k = k + 1 
                i = i + 2 
            elif (1-det) <= R:                      # deletion 
                target[i:(i+1)] = "" 
                ghost[k:k+1] = "%" 
                delcnt = delcnt + 1 
                k = k + 1 
                i = i 
            else: 
                ghost[k:k+1] = "-" 
                k = k + 1 
                i = i + 1 
        #print wt, ghost, target 
        j = j + 1 
        return [target, ghost] 
    #print "total insertion = ",inscnt 
    #print "total deletion = ",delcnt 
    #print "total randomization", mutcnt 
frag = [1,2,3,4,5,6,7,8] 
libsize = [4000, 10000, 4000, 4500, 23000, 4500, 20000, 20000] 
RIDfrag = 1 
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lib = libsize[RIDfrag-1] 
 
handle = open("C:\\Users\\Poyi\\Documents\\170mer-oligo-"+ str(RIDfrag) +".gbk", "rU") 
for record in SeqIO.parse(handle, "genbank") : 
    #print record.format('fasta') 
    #print record.features 
    id = record.id 
handle.close() 
myreport = [] 
k = 0 
while k < lib: 
    mutrecord = record 
    ghorecord = record 
    framelist = [] 
    for x in range(len(record.seq)): 
        framelist.append(0) 
    #print framelist 
    mutframe = 0 
    ghoframe = 0 
    for feat in record.features: 
        if feat.type == 'misc_feature':                 #pick the mutation features  
            start = feat.location.start 
            end = feat.location.end 
            featseq = record[start:end]                 #extract feature seq 
            #print featseq 
            #print featseq.seq 
            #print start, end 
            mut = RID(featseq.seq, 0.03, 0.05, 1)       #replace feature with RID seq 
            #print mut[0] 
            mutrecord.id = id + '-mut' + str(k+1) 
            z = []                 #amend the framelist right AFTER the end of feature 
            for y in framelist[end:]: 
                z = z + [y + (len(mut[0]) - len(featseq.seq))] 
            framelist[end:] = z 
            #print framelist 
            mutrecord = mutrecord[:start + framelist[start]] + mut[0] + mutrecord[end 
+ framelist[start]:]  #can add start-end frame check later. 
            #print mutrecord 
            ghorecord = ghorecord[:start + ghoframe] + mut[1] + ghorecord[end + 
ghoframe:] 
            mutframe = mutframe + (len(mut[0]) - len(featseq.seq)) 
            ghoframe = ghoframe + (len(mut[1]) - len(featseq.seq)) 
    #print ghorecord.seq 
    if len(mutrecord.seq) > 170: 
        k = k 
    else: 
        myreport.append(mutrecord) 
        print mutrecord.format('fasta') 
        k = k + 1 
SeqIO.write(myreport, "170mer-"+str(RIDfrag)+"-mut.fasta", 'fasta')  
 
Appendix B: Sequences  
Sequences of templates used in ribosome mutant selection 
DNA1/12: 
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GGCGTAATACGACTCACTATAGGGTTAACTTTAACAAGGAGAAAAACATggattacaagga
tgacgacgataagatcAAAagtctgattTAGgtagatcgcgttatcTGCatggaaaacgccatgTAGtggaacctgcctgccgat
ctcgcctggtttaaaTAGaacaccttaaataaacccgtgattatgTGCcgcTAGacctgggaatcaatcCATcgtccgttgccaG
CGTAGaaaaatATTATCCTCAGCAGTCAACCGCATACGTAGGATCGCGTAACGTGGGTG
AAGTCGGTGGATGAATAGATCGCGGCGTGTCATGACGTACCAGAAATCATGTAGAT
TGCGGCGCATCGCGTTTATGAACAGTTCTTGTAGAAGGCGCAAAAACTGTATCTGAC
GCATATCGACTAGGAAGTGGAAGCGGACACCCATTTCCCGGATTACTAGCCGGATG
ACTGGGAATCGGTATTCAGCGAATTCTAGGATGCTGATGCGCAGAACTCT 
DNA1/6: 
GGCGTAATACGACTCACTATAGGGTTAACTTTAACAAGGAGAAAAACATggattacaagga
tgacgacgataagatcAAAagtctgattTAGgtagatcgcgttatcTAGatggaaaacgccatgTAGtggaacctgcctgccTA
GctcgcctggtttaaaTAGaacaccttaaataaaTAGgtgattatgTGCcgcTAGacctgggaatcaatcTAGcgtccgttgcc
aGCGTAGaaaaatATTATCCTCTAGAGTCAACCGCATACGTAGGATCGCGTAACGTGGT
AGAAGTCGGTGGATGAATAGATCGCGGCGTGTCATTAGGTACCAGAAATCATGTAG
ATTGCGGCGCATCGCTAGTATGAACAGTTCTTGTAGAAGGCGCAAAAACTGTAGCTG
ACGCATATCGACTAGGAAGTGGAAGCGGACTAGCATTTCCCGGATTACTAGCCGGA
TGACTGGGAATAGGTATTCAGCGAATTCTAGGATGCTGATGCGCAGTAGTCT 
DNA3/6: 
GGCGTAATACGACTCACTATAGGGTTAACTTTAACAAGGAGAAAAACATggattacaagga
tgacgacgataagatcAAAagtctgattTAGgtagatTAGgttatcTAGatggaaTAGgccatgTAGtggaacTAGcctg
ccTAGctcgccTAGtttaaaTAGaacaccTAGaataaaTAGgtgattTAGTGCcgcTAGacctggTAGtcaatcT
AGcgtccgTAGccaGCGTAGaaaaatTAGATCCTCTAGAGTCAATAGCATACGTAGGATCGC
TAGACGTGGTAGAAGTCGTAGGATGAATAGATCGCGTAGTGTCATTAGGTACCATA
GATCATGTAGATTGCGTAGCATCGCTAGTATGAATAGTTCTTGTAGAAGGCGTAGAA
ACTGTAGCTGACGTAGATCGACTAGGAAGTGTAGGCGGACTAGCATTTCTAGGATTA
CTAGCCGGATTAGTGGGAATAGGTATTCTAGGAATTCTAGGATGCTTAGGCGCAGTA
GTCT 
DNA2/6: 
GGCGTAATACGACTCACTATAGGGTTAACTTTAACAAGGAGAAAAACATggattacaagga
tgacgacgataagatcAAAagtctgTAGTAGgtagatcgcgttTAGTAGatggaaaacgccTAGTAGtggaacctgcct
TAGTAGctcgcctggtttTAGTAGaacaccttaaatTAGTAGgtgattatgTGCTAGTAGacctgggaatcaTAG
TAGcgtccgttgccaTAGTAGaaaaatATTATCTAGTAGAGTCAACCGCATTAGTAGGATCGCG
TAACGTAGTAGAAGTCGGTGGATTAGTAGATCGCGGCGTGTTAGTAGGTACCAGAA
ATCTAGTAGATTGCGGCGCATTAGTAGTATGAACAGTTCTAGTAGAAGGCGCAAAA
ATAGTAGCTGACGCATATCTAGTAGGAAGTGGAAGCGTAGTAGCATTTCCCGGATTA
GTAGCCGGATGACTGGTAGTAGGTATTCAGCGATGCTGATGCGCAGTAGTCT 
DNA3/12: 
GGCGTAATACGACTCACTATAGGGTTAACTTTAACAAGGAGAAAAACATggattacaagga
tgacgacgataagatcAAAagtTAGTAGTAGgtagatcgcgttatcTGCatggaaaacTAGTAGTAGtggaacctgc
ctgccgatctcgcctggTAGTAGTAGaacaccttaaataaacccgtgattatgTAGTAGTAGgcctgggaatcaatcCAT
cgtccgttgTAGTAGTAGaaaaatATTATCCTCAGCAGTCAACCGTAGTAGTAGGATCGCGTA
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ACGTGGGTGAAGTCGGTGTAGTAGTAGATCGCGGCGTGTCATGACGTACCAGAATA
GTAGTAGcTTGCGGCGCATCGCGTTTATGAACAGTAGTAGTAGAAGGCGCAAAAACT
GTATCTGACGCATTAGTAGTAGGAAGTGGAAGCGGACACCCATTTCCCGTAGTAGTA
GCCGGATGACTGGGAATCGGTATTCAGCGATGCTGATGCGCAGAACTCT 
Appendix C: Lists of Mutations in Selected Mutants 
Mutations in mutant G2-G5, NP1-NP5 (whether it is programmed by chip oligos)
RID-G1 
A592T (No) 
T596A (No) 
A599G (No) 
A602G (No) 
G605C (No) 
C623G (No) 
A626T (No) 
G629C (No) 
C634G (No) 
A637G (No) 
C645T (No) 
T646A (No) 
T653C (No) 
A654T (No) 
T658C (No) 
A661T (No) 
T665A (No) 
C680G (No) 
T683C (No) 
G690T (No) 
A743C (Yes) 
T744C (Yes) 
G745T (Yes) 
A753G (Yes) 
T766C (No) 
C772A (No) 
G774C (No) 
G777A (Yes) 
C787T (Yes) 
A794G (No) 
C796T (No) 
G797C (No) 
C816T (No) 
G841A (No) 
A844T (No) 
T846- (No) 
T850C (No) 
C851T (No) 
T852G (No) 
C853T (No) 
C854A (No) 
A877T (No) 
C901A (No) 
G914C (No) 
G923T (No) 
G924A (No) 
A925C (No) 
G926A (No) 
A928G (No) 
T931C (No) 
T932C (No) 
-932G (No) 
T934G (No) 
C937T (No) 
G974A (No) 
C994T (No) 
C1013T (No) 
C1044T (No) 
C1045T (No) 
C1053T (No) 
T1058G (No) 
T1078C (No) 
A1080C (No) 
G1106A (No) 
-1141C (No) 
G1149A (No) 
G1160A (No) 
C1164- (No) 
A1165- (No) 
C1167T (No) 
G1168A (No) 
A1169T (No) 
G1171A (No) 
C1172T (No) 
T1173C (No) 
A1175T (No) 
T1176C (No) 
C1178G (No) 
G1179A (No) 
T1181G (No) 
G1182A (No) 
T1184G (No) 
G1185C (No) 
G1191A (No) 
C1211T (No) 
G1220A (No) 
C1229T (No) 
A1284- (No) 
T1513C (No) 
G1516A (No) 
G1537T (No) 
C1541T (No) 
G1581C (No) 
G1723A (No) 
A1784T (Yes) 
G1807A (No) 
G1869T (No) 
C1870A (No) 
A1872C (No) 
T1915G (No) 
T1979C (No) 
C1986G (No) 
A1987G (No) 
G1988C (No) 
C2021A (No) 
T2132A (No) 
T2203G (No) 
A2211G (No) 
total number of 
mutations = 108 
 
RID-G2 
A592T (No) 
T596A (No) 
A599G (No) 
A602G (No) 
G605C (No) 
C623G (No) 
A626T (No) 
G629C (No) 
C634G (No) 
C645T (No) 
T646A (No) 
T653C (No) 
A654T (No) 
T658C (No) 
A661T (No) 
T665A (No) 
C680G (No) 
T683C (No) 
G690T (No) 
A743C (Yes) 
T744C (Yes) 
G745T (Yes) 
A753G (Yes) 
T766C (No) 
C772A (No) 
G774C (No) 
G777A (Yes) 
C787T (Yes) 
A794G (No) 
C796T (No) 
G797C (No) 
C816T (No) 
G841A (No) 
A844T (No) 
T846- (No) 
T850C (No) 
C851T (No) 
T852G (No) 
C853T (No) 
C854A (No) 
A877T (No) 
C901A (No) 
G914C (No) 
G923T (No) 
G924A (No) 
A925C (No) 
G926A (No) 
A928G (No) 
T931C (No) 
T932C (No) 
-932G (No) 
T934G (No) 
C937T (No) 
G974A (No) 
C994T (No) 
C1013T (No) 
C1044T (No) 
C1045T (No) 
C1053T (No) 
T1058G (No) 
T1078C (No) 
A1080C (No) 
G1106A (No) 
-1141C (No) 
G1149A (No) 
G1160A (No) 
C1164- (No) 
A1165- (No) 
C1167T (No) 
G1168A (No) 
A1169T (No) 
G1171A (No) 
C1172T (No) 
T1173C (No) 
A1175T (No) 
T1176C (No) 
C1178G (No) 
G1179A (No) 
T1181G (No) 
G1182A (No) 
T1184G (No) 
G1185C (No) 
G1191A (No) 
C1211T (No) 
T1219A (No) 
C1221T (No) 
T1224A (No) 
G1227A (No) 
A1230T (No) 
G1245A (No) 
A1264G (No) 
A1276T (No) 
C1278G (No) 
G1280T (No) 
G1288A (No) 
C1290A (No) 
G1292C (No) 
T1294A (No) 
G1300A (No) 
G1311T (No) 
T1318C (No) 
C1319G (No) 
G1332A (No) 
G1333C (No) 
G1341T (No) 
A1347G (No) 
C1348T (No) 
C1363T (No) 
G1368A (No) 
G1382A (No) 
G1407C (No) 
G1408T (No) 
T1409G (No) 
C1414T (No) 
A1420T (No) 
G1423A (No) 
T1440G (No) 
T1442C (No) 
T1443C (No) 
G1444A (No) 
C1447T (No) 
G1448T (No) 
A1453T (No) 
C1454T (No) 
C1463A (No) 
G1464A (No) 
C1472G (No) 
G1473T (No) 
T1474G (No) 
T1484A (No) 
T1485A (No) 
T1487C (No) 
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C1488T (No) 
C1489T (No) 
C1493T (No) 
A1502G (No) 
A1504T (No) 
A1505T (No) 
T1506C (No) 
C1507T (No) 
T1513C (No) 
G1517A (No) 
C1518G (No) 
G1519C (No) 
G1530T (No) 
-1532T (No) 
-1532C (No) 
-1532T (No) 
C1533T (No) 
A1535T (No) 
C1536A (No) 
G1538A (No) 
C1541A (No) 
T1542C (No) 
C1547T (No) 
A1548G (No) 
A1549G (No) 
C1550T (No) 
A1551T (No) 
A1552G (No) 
C1558A (No) 
G1567A (No) 
C1575T (No) 
A1583T (No) 
A1593C (No) 
T1594A (No) 
C1595G (No) 
A1596G (No) 
T1599C (No) 
G1723A (No) 
T1725C (No) 
C1726G (No) 
C1727A (No) 
C1730T (No) 
G1733T (No) 
G1734C (No) 
A1735G (No) 
G1792C (No) 
T1915G (No) 
total number of 
mutations = 179 
 
RID-G3 
A592T (No) 
T596A (No) 
A599G (No) 
A602G (No) 
G605C (No) 
C623G (No) 
A626T (No) 
G629C (No) 
C634G (No) 
C645T (No) 
T646A (No) 
T653C (No) 
A654T (No) 
T658C (No) 
A661T (No) 
T665A (No) 
C680G (No) 
T683C (No) 
G690T (No) 
A743C (Yes) 
T744C (Yes) 
G745T (Yes) 
A753G (Yes) 
T766C (No) 
C772A (No) 
G774C (No) 
G777A (Yes) 
C787T (Yes) 
A794G (No) 
C796T (No) 
G797C (No) 
C816T (No) 
C838A (No) 
G841A (No) 
A844T (No) 
T846- (No) 
T850C (No) 
C851T (No) 
T852G (No) 
C853T (No) 
C854A (No) 
A877T (No) 
C901A (No) 
C908T (No) 
G914C (No) 
G923T (No) 
G924A (No) 
A925C (No) 
G926A (No) 
A928G (No) 
T931C (No) 
T932C (No) 
-932G (No) 
T934G (No) 
C937T (No) 
G974A (No) 
C994T (No) 
C1013T (No) 
C1044T (No) 
C1045T (No) 
C1053T (No) 
T1058G (No) 
T1078C (No) 
A1080C (No) 
G1106A (No) 
-1141C (No) 
G1149A (No) 
G1160A (No) 
C1164- (No) 
A1165- (No) 
C1167T (No) 
G1168A (No) 
A1169T (No) 
G1171A (No) 
C1172T (No) 
T1173C (No) 
A1175T (No) 
T1176C (No) 
C1178G (No) 
G1179A (No) 
T1181G (No) 
G1182A (No) 
T1184G (No) 
G1185C (No) 
G1191A (No) 
C1211T (No) 
T1219A (No) 
C1221T (No) 
T1224A (No) 
G1227A (No) 
A1230T (No) 
A1264G (No) 
A1276T (No) 
C1278G (No) 
G1280T (No) 
G1288A (No) 
C1290A (No) 
G1292C (No) 
T1294A (No) 
G1300A (No) 
G1311T (No) 
T1318C (No) 
C1319G (No) 
G1332A (No) 
G1333C (No) 
G1341T (No) 
A1347G (No) 
C1348T (No) 
C1363T (No) 
G1368A (No) 
G1382A (No) 
G1407C (No) 
G1408T (No) 
T1409G (No) 
C1414T (No) 
A1420T (No) 
G1423A (No) 
T1440G (No) 
T1442C (No) 
T1443C (No) 
G1444A (No) 
C1447T (No) 
G1448T (No) 
A1453T (No) 
C1454T (No) 
C1463A (No) 
G1464A (No) 
C1472G (No) 
G1473T (No) 
T1474G (No) 
T1484A (No) 
T1485A (No) 
T1487C (No) 
C1488T (No) 
C1489T (No) 
C1493T (No) 
A1502G (No) 
A1504T (No) 
A1505T (No) 
T1506C (No) 
C1507T (No) 
T1513C (No) 
G1517A (No) 
C1518G (No) 
G1519C (No) 
G1530T (No) 
-1532T (No) 
-1532C (No) 
-1532T (No) 
C1533T (No) 
A1535T (No) 
C1536A (No) 
G1538A (No) 
C1541A (No) 
T1542C (No) 
C1547T (No) 
A1548G (No) 
A1549G (No) 
C1550T (No) 
A1551T (No) 
A1552G (No) 
C1558A (No) 
G1567A (No) 
C1575T (No) 
A1583T (No) 
A1593C (No) 
T1594A (No) 
C1595G (No) 
A1596G (No) 
T1599C (No) 
C1625T (No) 
A1626G (No) 
T1683C (No) 
G1684A (No) 
C1704T (No) 
A1705G (No) 
T1709C (No) 
A1711- (No) 
T1712- (No) 
A1713G (No) 
T1716A (No) 
A1717G (No) 
G1723A (No) 
T1725- (No) 
C1726G (No) 
C1727A (No) 
C1730T (No) 
G1733T (No) 
G1734C (No) 
A1735C (No) 
T1736G (No) 
G1737T (No) 
G1738A (No) 
G1743C (No) 
A1745T (No) 
A1746G (No) 
T1747C (No) 
A1749G (No) 
C1764G (No) 
T1765C (No) 
G1766C (No) 
A1772G (No) 
G1797C (No) 
C1822G (No) 
G1869T (No) 
C1870A (No) 
A1872C (No) 
T1915G (No) 
T1979C (No) 
C1986G (No) 
A1987G (No) 
G1988C (No) 
C2021A (No) 
C2043T (No) 
A2051T (No) 
G2087T (No) 
A2088G (No) 
A2094G (No) 
A2097T (No) 
G2102A (No) 
C2103T (No) 
C2104T (No) 
T2106G (No) 
G2107C (No) 
A2108T (No) 
T2137C (No) 
C2150T (No) 
T2151C (No) 
A2154G (No) 
G2162A (No) 
T2181G (No) 
T2182G (No) 
A2183C (No) 
T2185A (No) 
G2186C (No) 
T2192G (No) 
G2201T (No) 
T2202C (No) 
T2203A (No) 
A2205G (No) 
C2206T (No) 
A2211T (No) 
G2218A (No) 
T2220C (No) 
C2222A (No) 
C2232A (No) 
C2283T (No) 
T2292G (No) 
G2293C (No) 
A2297C (No) 
T2299G (No) 
C2300A (No) 
T2302C (No) 
C2310A (No) 
A2314G (No) 
G2316T (No) 
A2317C (No) 
G2319T (No) 
T2320A (No) 
T2321G (No) 
G2325A (No) 
C2326T (No) 
T2329A (No) 
T2334A (No) 
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C2339G (No) 
A2340C (No) 
C2354A (No) 
G2355C (No) 
T2356A (No) 
G2360A (No) 
G2361C (No) 
C2362G (No) 
G2363T (No) 
T2533C (No) 
A2534C (No) 
total number of 
mutations = 275 
 
RID-G4 
A592T (No) 
T596A (No) 
A599G (No) 
A602G (No) 
G605C (No) 
C623G (No) 
A626T (No) 
G629C (No) 
C634G (No) 
C645T (No) 
T646A (No) 
T653C (No) 
A654T (No) 
T658C (No) 
A661T (No) 
T665A (No) 
C680G (No) 
T683C (No) 
G690T (No) 
A743C (Yes) 
T744C (Yes) 
G745T (Yes) 
A753G (Yes) 
T766C (No) 
C772A (No) 
G774C (No) 
G777A (Yes) 
C787T (Yes) 
A794G (No) 
C796T (No) 
G797C (No) 
C816T (No) 
G841A (No) 
A844T (No) 
T846- (No) 
T850C (No) 
C851T (No) 
T852G (No) 
C853T (No) 
C854A (No) 
A877T (No) 
C901A (No) 
G914C (No) 
G923T (No) 
G924A (No) 
A925C (No) 
G926A (No) 
A928G (No) 
T931C (No) 
T932C (No) 
-932G (No) 
T934G (No) 
C937T (No) 
G974A (No) 
C994T (No) 
C1013T (No) 
C1044T (No) 
C1045T (No) 
C1053T (No) 
T1058G (No) 
T1078C (No) 
A1080C (No) 
G1106A (No) 
-1141C (No) 
G1149A (No) 
G1160A (No) 
C1164- (No) 
A1165- (No) 
C1167T (No) 
G1168A (No) 
A1169T (No) 
G1171A (No) 
C1172T (No) 
T1173C (No) 
A1175T (No) 
T1176C (No) 
C1178G (No) 
G1179A (No) 
T1181G (No) 
G1182A (No) 
T1184G (No) 
G1185C (No) 
G1191A (No) 
C1211T (No) 
T1219A (No) 
C1221T (No) 
T1224A (No) 
G1227A (No) 
A1230T (No) 
A1264G (No) 
A1276T (No) 
C1278G (No) 
G1280T (No) 
G1288A (No) 
C1290A (No) 
G1292C (No) 
T1294A (No) 
G1300A (No) 
G1311T (No) 
T1318C (No) 
C1319G (No) 
G1332A (No) 
G1333C (No) 
G1341T (No) 
A1347G (No) 
C1348T (No) 
C1363T (No) 
G1368A (No) 
G1382A (No) 
G1407C (No) 
G1408T (No) 
T1409G (No) 
C1414T (No) 
A1420T (No) 
G1423A (No) 
T1440G (No) 
T1442C (No) 
T1443C (No) 
G1444A (No) 
C1447T (No) 
G1448T (No) 
A1453T (No) 
C1454T (No) 
C1463A (No) 
G1464A (No) 
C1472G (No) 
G1473T (No) 
T1474G (No) 
T1484A (No) 
T1485A (No) 
T1487C (No) 
C1488T (No) 
C1489T (No) 
C1493T (No) 
A1502G (No) 
A1504T (No) 
A1505T (No) 
T1506C (No) 
C1507T (No) 
T1513C (No) 
G1517A (No) 
C1518G (No) 
G1519C (No) 
G1530T (No) 
-1532T (No) 
-1532C (No) 
-1532T (No) 
C1533T (No) 
A1535T (No) 
C1536A (No) 
G1538A (No) 
C1541A (No) 
T1542C (No) 
C1547T (No) 
A1548G (No) 
A1549G (No) 
C1550T (No) 
A1551T (No) 
A1552G (No) 
C1558A (No) 
G1567A (No) 
C1575T (No) 
A1583T (No) 
A1593C (No) 
T1594A (No) 
C1595G (No) 
A1596G (No) 
T1599C (No) 
C1625T (No) 
A1626G (No) 
T1683C (No) 
G1684A (No) 
C1704T (No) 
A1705G (No) 
T1709C (No) 
A1711- (No) 
T1712- (No) 
A1713G (No) 
T1716A (No) 
A1717G (No) 
G1723A (No) 
T1725- (No) 
C1726G (No) 
C1727A (No) 
C1730T (No) 
G1733T (No) 
G1734C (No) 
A1735C (No) 
T1736G (No) 
G1737T (No) 
G1738A (No) 
G1743C (No) 
A1745T (No) 
A1746G (No) 
T1747C (No) 
A1749G (No) 
C1764G (No) 
T1765C (No) 
G1766C (No) 
A1772G (No) 
G1797C (No) 
C1822G (No) 
G1869T (No) 
C1870A (No) 
A1872C (No) 
T1915G (No) 
T1979C (No) 
C1986G (No) 
A1987G (No) 
G1988C (No) 
C2043T (No) 
G2140A (No) 
T2203G (No) 
A2211G (No) 
T2629C (No) 
total number of 
mutations = 215 
 
RID-G5 
A592T (No) 
T596A (No) 
A599G (No) 
A602G (No) 
G605C (No) 
C623G (No) 
A626T (No) 
G629C (No) 
C634G (No) 
C645T (No) 
T646A (No) 
T653C (No) 
A654T (No) 
T658C (No) 
A661T (No) 
T665A (No) 
C680G (No) 
T683C (No) 
G690T (No) 
A743C (Yes) 
T744C (Yes) 
G745T (Yes) 
A753G (Yes) 
T766C (No) 
C772A (No) 
G774C (No) 
G777A (Yes) 
C787T (Yes) 
A794G (No) 
C796T (No) 
G797C (No) 
C816T (No) 
G841A (No) 
A844T (No) 
T846- (No) 
T850C (No) 
C851T (No) 
T852G (No) 
C853T (No) 
C854A (No) 
A877T (No) 
C901A (No) 
G914C (No) 
G923T (No) 
G924A (No) 
A925C (No) 
G926A (No) 
A928G (No) 
T931C (No) 
T932C (No) 
-932G (No) 
T934G (No) 
C937T (No) 
G974A (No) 
C994T (No) 
C1013T (No) 
C1044T (No) 
C1045T (No) 
C1053T (No) 
T1058G (No) 
T1078C (No) 
A1080C (No) 
G1106A (No) 
-1141C (No) 
G1149A (No) 
G1160A (No) 
C1164- (No) 
A1165- (No) 
C1167T (No) 
G1168A (No) 
A1169T (No) 
G1171A (No) 
C1172T (No) 
T1173C (No) 
A1175T (No) 
T1176C (No) 
C1178G (No) 
G1179A (No) 
T1181G (No) 
G1182A (No) 
T1184G (No) 
  
87 
 
G1185C (No) 
G1191A (No) 
C1211T (No) 
T1219A (No) 
C1221T (No) 
T1224A (No) 
G1227A (No) 
A1230T (No) 
A1264G (No) 
A1276T (No) 
C1278G (No) 
G1280T (No) 
G1288A (No) 
C1290A (No) 
G1292C (No) 
T1294A (No) 
G1300A (No) 
G1311T (No) 
T1318C (No) 
C1319G (No) 
G1332A (No) 
G1333C (No) 
G1341T (No) 
A1347G (No) 
C1348T (No) 
C1363T (No) 
G1368A (No) 
G1382A (No) 
G1407C (No) 
G1408T (No) 
T1409G (No) 
C1414T (No) 
A1420T (No) 
G1423A (No) 
T1440G (No) 
T1442C (No) 
T1443C (No) 
G1444A (No) 
C1447T (No) 
G1448T (No) 
A1453T (No) 
C1454T (No) 
C1463A (No) 
G1464A (No) 
C1472G (No) 
G1473T (No) 
T1474G (No) 
T1484A (No) 
T1485A (No) 
T1487C (No) 
C1488T (No) 
C1489T (No) 
C1493T (No) 
A1502G (No) 
A1504T (No) 
A1505T (No) 
T1506C (No) 
C1507T (No) 
T1513C (No) 
G1517A (No) 
C1518G (No) 
G1519C (No) 
G1530T (No) 
-1532T (No) 
-1532C (No) 
-1532T (No) 
C1533T (No) 
A1535T (No) 
C1536A (No) 
G1538A (No) 
C1541A (No) 
T1542C (No) 
C1547T (No) 
A1548G (No) 
A1549G (No) 
C1550T (No) 
A1551T (No) 
A1552G (No) 
C1558A (No) 
G1567A (No) 
C1575T (No) 
A1583T (No) 
A1593C (No) 
T1594A (No) 
C1595G (No) 
A1596G (No) 
T1599C (No) 
C1625T (No) 
A1626G (No) 
T1683C (No) 
G1684A (No) 
C1704T (No) 
A1705G (No) 
T1709C (No) 
A1711- (No) 
T1712- (No) 
A1713G (No) 
T1716A (No) 
A1717G (No) 
G1723A (No) 
T1725- (No) 
C1726G (No) 
C1727A (No) 
C1730T (No) 
G1733T (No) 
G1734C (No) 
A1735C (No) 
T1736G (No) 
G1737T (No) 
G1738A (No) 
G1743C (No) 
A1745T (No) 
A1746G (No) 
T1747C (No) 
A1749G (No) 
C1764G (No) 
T1765C (No) 
G1766C (No) 
A1772G (No) 
G1797C (No) 
C1822G (No) 
G1869T (No) 
C1870A (No) 
A1872C (No) 
T1915A (No) 
T1979C (No) 
C1986G (No) 
A1987G (No) 
G1988C (No) 
C2021A (No) 
T2203G (No) 
A2211G (No) 
total number of 
mutations = 213 
 
RID-NP1 
G745C (Yes) 
A1134T (No) 
C1164T (No) 
C1178T (No) 
C1196T (No) 
G1831A (No) 
T1915A (No) 
G1989A (No) 
G2487A (No) 
total number of 
mutations = 9 
 
RID-NP2 
G745T (Yes) 
A1230G (No) 
C1357T (No) 
T1915C (No) 
T2132A (No) 
T2203G (No) 
A2211G (No) 
C2374T (No) 
total number of 
mutations = 8 
 
RID-NP3 
G745T (Yes) 
C1150T (No) 
A1269T (No) 
G1723A (No) 
T1865C (No) 
T1915C (No) 
T2203G (No) 
A2211G (No) 
G2444- (Yes) 
G2445- (Yes) 
C2575T (Yes) 
total number of 
mutations = 11 
 
RID-NP4 
G745T (Yes) 
C915T (No) 
G1171A (No) 
T1173- (No) 
C1178T (No) 
C1211T (No) 
G1220A (No) 
C1229T (No) 
T1484G (No) 
T1513C (No) 
C1541T (No) 
G1723A (No) 
T1915G (No) 
T2132A (No) 
T2166C (No) 
G2623T (No) 
total number of 
mutations = 16 
 
RID-NP5 
A626G (No) 
T744- (Yes) 
G745T (Yes) 
C957T (Yes) 
G1171A (No) 
T1173- (No) 
A1175G (No) 
C1178T (No) 
C1211T (No) 
G1220A (No) 
C1229T (No) 
G1723A (No) 
C1730T (No) 
G1869T (No) 
C1870A (No) 
A1872C (No) 
-1891C (No) 
T1915G (No) 
C1974T (No) 
T1979C (No) 
C1986G (No) 
A1987G (No) 
G1988C (No) 
T2493C (Yes) 
total number of 
mutations = 24 
 
